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ABSTRACT
Many skeletal diseases, such as osteoporosis and malignant bone metastases, are
generally osteolytic and associated with increased bone resorption and decreased bone
strength. Within a complex cytokine environment, the proteins RANKL and M-CSF are
critical for osteoclast differentiation and activation, and thus fundamental effectors of
osteolytic disorders. Previous studies showed that M-CSF stimulates the proliferation and
early differentiation of osteoclast progenitors to osteoclast lineage, while RANKL targets
the later stages of fusion and activation, and stimulates the formation of functional active
osteoclasts. However, impacts of artificially elevated levels of these proteins on the
skeleton system have not been fully characterized.
In this project, we amplified the circulating levels of RANKL and M-CSF by
injections or continuous administrations and examined the effects on bone volume and
quality. We hypothesized that while M-CSF and RANKL can both stimulate
osteoclastogenesis, the differences in activation stages targeted by these two cytokines
would result in distinct responses on bone biomechanics. RANKL would directly
stimulate osteoclast activity and increase bone resorption, while M-CSF would act
anabolically through coupling between osteoblast development and the promoted
osteoclastogenesis at the early stage, and promote bone formation indirectly.
Data obtained in this project demonstrated that in vivo administration of RANKL
and M-CSF induced general opposing effects on bone volume, architecture,
mineralization and strength. RANKL directly stimulated bone resorption and reduceed
bone biomechanical properties. The destructive skeleton induced by RANKL could serve
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as a novel animal model that exhibits a series of skeletal complications similar to those
observed in osteolytic skeletal diseases, such as osteoporosis. Alternately, administrations
of M-CSF markedly stimulated trabecular bone formation and had less of an influence on
cortical bone. These changes demonstrated the potential of M-CSF as an anabolic agent
for osteoporosis.
This project has further examined the in vivo characteristics and functional effects
of RANKL and M-CSF on the skeleton system. Findings in this project, such as the
creation of RANKL induced bone loss model and characterization of the anabolic
potential of M-CSF on the skeleton, could provide useful information and tools for
further explorations on human skeletal diseases.
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CHAPTER 1
INTRODUCTION
1.1 General Bone Biology
1.1.1 Component and Function
Bone is a specialized connective tissue composed of cells and extracellular
matrix. Bone matrix is formed by collagen fibers (type I, 90% of the total protein),
noncollagenous proteins, and inorganic minerals. Collagen fibers are oriented in specific
directions and contribute to the flexibility and the great tensile strength of bone (ViguetCarrin, Garnero et al. 2006). Mineral crystals (primarily hydroxyapatite, accounting for
65% of bone mass) surround and attach to the collagen fibers using the noncollagenous
proteins, allowing bone to resist compression with its exceptional hardness (Buckwalter
and Cooper 1987).
Two primary types of bones make up the skeletal system (Figure 1.1). Cortical
bone is the hard, outer shell that comprises 80% of the skeletal system (by mass). It
exhibits advanced mineralization and has a slow turnover rate. Mature cortical bone
consists of small units called osteons, which are organized in concentric layers of bone
that surround a vascular channel. The other type of bone is trabecular bone (also known
as cancellous or spongy bone). Trabecular bone is a network of small, connected struts
that is weaker than cortical bone and located at the epiphyses of long bones and
throughout the interior of short bones. Cancellous bone has a much higher turnover rate
than cortical bone; therefore it is typically less mineralized (Heaney 2003).
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Figure 1.1 Diagram showing basic bone structure (http://www.abdn.ac.uk/orthopaedics)

Bone, together with cartilage, makes up the skeletal system and provides several
essential functions to life. First, bones connect to each other by ligaments and provide
both the framework of the body and mechanical support for movement (Kell, Bell et al.
2001). Skeletal muscles attach to bones via tendons, and use bones as levers to move the
body. Second, bones provide protection for the vital organs. For instance, the central
nervous system is protected by the skull, and ribs protect the cardiovascular organs. The
third function of bone is to serve as a reservoir for vital minerals (primarily calcium and
phosphate). Calcium is an essential element that maintains and regulates a number of
physiological activities; approximately 99% of the body’s calcium is stored in the
skeleton in the form of hydroxyapatite and can be released into the blood stream for
distribution to body parts when needed (Specker 1996). Finally, the marrow cavities in
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certain bones (i.e. long bones) provide the microenvironment for blood cell formation
(hematopoiesis).
1.1.2 Bone Remodeling
Bone is a dynamic tissue. In a mature skeleton, bone is continuously being broken
down (bone resorption) and reformed (bone formation), allowing for the maintenance of
bone tissue. This coordinated process is called bone remodeling. Bone remodeling is
directed by the actions of the two major bone cells: osteoclasts (cells responsible for bone
resorption) and osteoblasts (cells responsible for bone formation) (Parfitt 1984). The
sequence of bone remodeling is always with resorption occurring first via active
osteoclasts, followed by formation to form new bone tissue and resolve the defect
(Ljunggren, Ljunghall et al. 1995).
1.1.2.1 Bone Resorption by Osteoclasts
Osteoclasts are giant multinucleated cells that differentiate from hematopoietic
precursors of the monocyte/macrophage lineage (Udagawa, Takahashi et al. 1990). They
are typically located in contact with a calcified bone surface or within a lacuna
(Howship’s lacunae), usually with one or two in each resorption site (Vaananen,
Hentunen et al. 1988). A most important feature of osteoclasts is the ruffled borders
formed by deep foldings of plasma membranes in the area facing bone matrix (Figure
1.2): The ruffled border is centrally located and surrounded by a ring of actin that serves
to attach the cell to the bone surface, thus sealing off the bone resorbing compartment
(Vaananen, Zhao et al. 2000).
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Figure 1.2 Scanning electron micrograph showing an active osteoclast (Bone Research Society,
www. brsoc.org.uk)

When bone matrix is undergoing bone resorption by osteoclasts, lysosomal
enzymes (Tartrate Resistant Acid Phosphatase, cathepsin K, etc.) are secreted into the
extracellular bone resorbing compartment through the ruffled border (Zaidi, Pazianas et
al. 1993). Since this compartment is sealed from the surrounding marrow cavity, enzymes
are able to reach a high concentration. Accompanied with the lysosomal enzymes,
protons are secreted by osteoclasts using proton pumps and across the ruffled border, thus
causing an increase in the acidity of the extracellular compartment (Vaananen, Zhao et al.
2000). Therefore, the extracellular bone resorbing compartment is functionally equivalent
to a lysosome with low pH, high concentration lysosomal enzymes, and the substrate
(bone matrix, figure 1.3). Resorption starts with the hydroxyapatite crystals being
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mobilized by digestion of their links (the non-collagenous proteins) with collagen and
dissolved by the acid environment. Then, the residual collagen fibers are digested either
by the activation of collagenase or by the action of cathepsins at low pH. Residues from
this extracellular digestion are internalized, transported through the cell and released at
the basolateral domain, or released during the periods of relapse of the sealing zone
(Lerner 2000).

Figure 1.3 Picture illustrating osteoclastic bone resorption. The differentiated osteoclast polarizes
on the bone surface, which involves matrix-derived signals transmitted by the αvβ3 integrin.
After formation of the ruffled membrane, the osteoclast acidifies an extracellular
microenvironment by means of an electrogenic proton pump. Intracellular pH is maintained by
HCO3-/Cl- exchange at the cell’s antiresorptive surface. Cl- ions pass through a ruffled membraneresiding anion channel into the resorptive microenvironment, which achieves a pH approximating
4.5. The acidic milieu mobilizes the mineral phase of bone and provides an optimal environment
for organic matrix degradation by cathepsin K (Teitelbaum 2000).

1.1.2.2 Bone Formation by Osteoblasts
Osteoblasts are bone lining cells that are responsible for the production of bone
matrix (collagens and ground substance). Osteoblasts originate from bone marrow
stromal stem cells and connective tissue mesenchymal stem cells; under the regulation of
a series of growth factors and cytokines, osteoblast progenitors proliferate and
differentiate into preosteoblasts and then mature osteoblasts (Lian and Stein 1995). On
bone surfaces, osteoblasts connect to each other via adhering junctions and enable
intercellular communications; they function in clusters of around 100-400 cells along
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each bone forming site (Stains and Civitelli 2005). When they receive signals from bone
matrix, osteoblasts lay down osteoid (new bone matrix before it is mineralized) into bone
resorption sites. In humans, the osteoid exists for approximately 10 days before
mineralization is initiated, and the mineralized bone matrix is formed (Anderson 1989).
Osteocytes are osteoblasts and bone-lining cells that were trapped within the matrix
during the mineralization of bone. They are in direct communication with each other and
with surface osteoblasts through their cellular processes. These intercellular
communications have been indicated to play an important role in both the mineralization
of bone and the detection and response to mechanical forces within bone matrix (Rodan
1992).
1.1.2.3 Bone Remodeling Process
The process of bone remodeling can be divided into five stages (Parfitt 1984):
quiescence, activation, resorption, reversal, formation and then back to quiescence
(Figure 1.4). Quiescence refers to the resting state of bone surface. In this stage, the bone
surface is surrounded by elongated osteoblasts called bone lining cells (LC, Figure 1.4).
When bone remodeling is initiated, bone lining cells retract from the activated bone
surface and the exposed mineralized surface attracts circulating preosteoclasts (POC,
Figure 1.4) to aggregate, then fuse into multinucleated osteoclasts (activation phase).
Afterwards, osteoclasts (OC, Figure 1.4) become activated and start to resorb the
mineralized bone matrix during the resorption stage. In the reversal phase, cellular
activities on the resorbed bone surface switch from resorption by osteoclasts to
recruitment of osteoblasts. Osteoblasts aggregate on the bone resorption sites and then
start to deposit new bone matrix (formation phase).
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LC
1. Quiescence

POC
2. Activation

3. Resorption

4. Reversal

OC

OB

OB
5. Formation
LC
1. Quiescence

Figure 1.4 Bone remodeling phases. LC refers to bone lining cells (elongated osteoblasts), POC
refers to preosteoclasts, OC refers to osteoclasts, and OB refers to osteoblasts.

Bone remodeling is the result of interactions among multiple elements, including
osteoblasts, osteoclasts, hormones, growth factors, and cytokines (Mundy 1993). In a
healthy skeleton, activities of bone resorption and formation are coupled, meaning that
bone formation always occurs following the previous bone resorption, as the bone
remodeling process describes. The phenomena is largely related to the signals initiated
during bone matrix resorption and then transferred to osteoblasts and pre-osteoblasts via
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local regulatory network (Howard, Bottemiller et al. 1981; Locklin, Khosla et al. 2003).
Accordingly, a series of factors which can promote or inhibit osteoclastic bone resorption
result in similar stimulation or inhibition of osteoblast activation and bone formation
(Manolagas and Jilka 1995). Under normal conditions bone remodeling is a balanced
process that allows a renewal of 5-10% of bone volume each year (FernandezTresguerres-Hernandez-Gil, Alobera-Gracia et al. 2006). However, this balanced network
can be disrupted in some pathological conditions, leading to the onset of skeletal
diseases, including osteoporosis, osteopetrosis, Paget’s disease, and bone malignant
metastasis (Manolagas and Jilka 1995; Blair, Zhou et al. 2006).
1.1.3 Bone Biomechanics
As described at the beginning of this chapter, bone serves four major functions,
the first two relate to bone’s biomechanical role in the body. First, bones serve as levers
against muscle contractions and support body movement; second, bones shield vital
organs from trauma. Bone fragility, or bone strength, is used to indicate the
biomechanical status of bone, representing bone’s susceptibility to fracture (Turner
2002). Bone strength has many determinants, including the intrinsic properties of bone
tissue (bone material properties), bone mass (also referred as bone volume in preclinical
studies), and bone structural properties, such as bone size, cortical thickness, porosity,
and architecture (Turner 2002; Ammann and Rizzoli 2003; Burr 2004). Clinically, bone
strength is generally estimated by bone mineral density (BMD) using dual-energy X-ray
absorptiometry (DXA). DXA measures the amount of minerals (calcium) present in bone
and compares with normal data from specific age and race to predict fracture risk; it is the
most commonly used tool to clinically diagnose osteoporosis. However, as BMD itself
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only accounts for 60-70% of bone strength, many important factors cannot be captured by
DXA (Friedman 2006; Turner 2006). For instance, the fracture risk in a 75-year-old
woman is 4-7 times as that in a 45-year-old woman with identical BMD (Hui, Slemenda
et al. 1988). These important bone strength determinants, other than BMD, can be
broadly defined as bone quality (Burr 2004). Bone quality is mainly comprised of the
material properties of bone tissue and bone structural properties, and is also largely
influenced by bone turnover rates.
1.1.3.1 Material Properties of Bone
Bone tissue is a composite material composed mostly of type I collagen and
minerals. Type I collagen has little influence on the stiffness of bone, particularly in
compression, but has a profound effect on its toughness (Burr 2002; Wang, Shen et al.
2002). Regulated by the nature of applied stress on bone, collagen fibers grow in
preferential orientations (Martin and Ishida 1989) and contribute to the tensile strength of
bone (Riggs, Vaughan et al. 1993; Takano, Turner et al. 1999). Collagen fibers can also
enhance bone’s toughness by increasing the amount of cross-linking (Zioupos, Currey et
al. 1999). Studies have shown that the decreased extent of collagen fiber crosslinking
with aging reduces bone’s energy to failure, leading to increased fracture risk (Zioupos,
Currey et al. 1999). On the other hand, minerals contribute largely to bone’s stiffness and
resistance to compressive force due to its hardness. Most bone minerals exist in the form
of hydroxyapatite crystals: Ca10(PO4)6(OH)2. These calcium phosphate crystals have
spindle- or plate-like shapes and connect to collagen fibers via the non-collagenous
proteins (anionic complexes with high ion-binding capacities).
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In healthy bones, minerals and collagen fibers maintain a ratio that lead to
biomechanical properties sufficient to withstand normal loading of bone, but this ratio
varies in other conditions, leading to increased fracture risk (Currey, Brear et al. 1996).
For instance, bones from osteopetrotic patients (bone minerals over-accumulate,
hypermineralization) are very stiff, but also very brittle and result in reduced energy to
failure. In contrast, patients with osteomalacia have high turnover, less mineralized bone
(hypomineralization), which are ductile and can undergo large deformation without
breaking but are poorly mineralized and weak. Both hypo- and hypermineralization
reduce bone mechanical properties (Currey 1975; Currey, Brear et al. 1996).
1.1.3.2 Structural Properties of Bone
The structural properties of bone depend on mass distribution throughout the
structure. From the macroscopic perspective, bone size is an important component. With
the same cross-sectional area, bones with a larger diameter are stronger in resisting
bending stress than smaller bones with thicker cortical walls. Distribution of bone
materials further from the neutral axis of bone contributes to a higher polar moment of
inertia (pMOI, which is used to predict object’s ability to resist torsion, and also widely
used in bone engineering to predict cortical geometry and the ability to resist bending
load).
Besides bone size, intrinsic bone geometry also determines bone structural
properties and strength. Trabecular bone geometry is an important component of bone
structural properties. Trabecular bones exist at the ends of long bones and throughout the
inside of short bones. The small plate-like structures (individual trabeculae) of trabecular
bone are connected to each other to appropriately distribute forces throughout the shaft.
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In osteoporotic conditions, loss of trabecular connectivity decreases the capability of the
trabecular meshwork to effectively distribute forces. Without a great change in bone
mineral density, bone strength can be largely decreased due to the loss of connectivity
between trabeculae struts. This can be demonstrated by antiresorptive therapies on
osteoporosis patients: One-year treatment of bisphosphonates (a category of
antiresorptive treatment) decreased fracture risk by 50-60% with only 5% increase in
bone mineral density (Burr 2004).
Besides trabecular geometry, cortical bone geometry also contributes to the
structural properties of bone. Bone geometry change induced by anabolic treatments of
osteoporosis is a common example. Parathyroid hormone (Teriparatide, PTH I-34)
stimulates new bone formation at the periosteal (outside) surface and lowers fracture risk
in osteoporotic patients. At the same time, PTH also induces an increase in cortical
porosity and partly counteracts the positive effects on bone strength (Burr, Hirano et al.
2001). It is the deposition of bone at the periosteal surface, having a greater contribution
to torsional and bending moments of inertia, that more than compensates for this greater
porosity
1.1.3.3 Influence of Turnover on Bone Biomechanics
Bone turnover, which represents the rate bone is remodeled, is an important
determinant of bone quality (Heaney 2003). Normal bone turnover rates in healthy
individuals ensure the balance between old bone removal and new bone formation.
Variations in bone turnover interrupt bone remodeling balance and result in direct
changes in bone material and structural properties, as seen in aged people or patients with
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skeletal disease (Parfitt 2002). High or low bone turnover rate cause different changes in
bone material and structural properties, but both compromise bone biomechanics.
An abnormally high bone turnover results in increased bone resorption rates,
decreased bone mass, decreased bone mineralization, and decreased bone strength
(Heaney 2003). An extreme example with pathologically high bone turnover rates is
Paget’s disease. Symptoms of Paget’s disease include the presence of large, woven, less
mineralized bone and skeletal abnormity, bones are ductile and weak (Raisz 1999; Siris
1999; Whyte 2006). As described above, PTH as an anabolic agent increases overall bone
remodeling speed (turnover rate), resulting in increased cortical porosity (Turner 2002;
Burr 2005).
In contrast, an unusually low turnover rate leads to microdamage accumulation
and hypermineralization of bone matrix, resulting in brittle bone and increased risk of
fracture. Osteopetrosis is an extreme example of low bone turnover induced by defects in
osteoclast formation and function. In the skeletons of osteopetrosis patients, defects in
bone resorption induce accumulation of microdamage; bones are thick and dense but
brittle and abnormal (Tolar, Teitelbaum et al. 2004). Decreased bone turnover is usually
associated

with

antiresorptive

therapy

of

osteoporosis

(i.e.

bisphosphonates).

Bisphosphonates stimulate osteoclast apoptosis, inhibit osteoclastic bone resorption, and
decrease bone turnover. However, bisphosphonates also compromise the removal of
microdamaged bone and enable the accumulation of microfractures, thus degrade bone
quality. Potential long-term negative effects induced by bisphosphonates have attracted
much debate and concern recently; details will be discussed later in this chapter (Sibilia
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and Netti 1996; Rodan, Reszka et al. 2004; Iwamoto, Takeda et al. 2006; Liberman
2006).
1.2 Osteoclastogenesis
Osteoclasts are multinucleated giant cells responsible for bone resorption. They
maintain bone homeostasis by resorbing the old, damaged bones and initiate bone
remodeling. Among the various skeletal diseases known to occur in humans, the majority
of them are triggered by abnormalities in osteoclast development or function. These
osteoclast abnormalities can be divided into two distinct situations. First, the loss of
function in osteoclasts, due to problems in differentiation or abnormal apoptosis, leads to
osteopetrosis with little or no osteoclasts activity and a dense but brittle skeleton (Marks
1987; Tolar, Teitelbaum et al. 2004). On the other hand, excessive number and activity of
osteoclasts initiate osteolytic bone diseases, including osteoporosis, rheumatoid arthritis
and malignant bone metastases, resulting in bone loss, deterioration in architecture, and
decrease bone biomechanical properties (Teitelbaum 1996; Boyce, Xing et al. 2003).
Osteolytic bone diseases are most common (Rodan and Martin 2000), and are induced by
excessive level of osteoclastogenesis due to abnormalities in regulation signals that are
released into the bone microenvironment. Osteoclastogenesis regulation is a complicated
process, with many cells, hormones, and cytokines involved; exact mechanisms in
various situations are still unclear. Therefore, to better understand the skeletal diseases, it
is important to understand the osteoclastogenesis pathway and its regulation system.
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1.2.1 Origin of Osteoclasts
In the 1980s, significant debate and confusion existed on the origin of osteoclasts.
The classic concept was that osteoclasts originated from connective tissue cells, while
others hypothesized that it originated from mature hematopoietic cells, particularly from
monocyte or macrophage cells (Hanaoka, Yabe et al. 1989). In 1990, researchers using an
in vitro cell coculture system demonstrated that macrophages could differentiate into
osteoclasts with the presence of bone marrow stromal cells and their osteoblast
progenitors (Udagawa, Takahashi et al. 1990). This proved for the first time the concept
that osteoclasts are derived from haematopoietic stem cells of the monocyte/macrophage
lineage in the bone marrow.
Hematopoietic stem cell precursors first undergo a phase of determination to
acquire the potential of becoming either osteoclasts or macrophages. After proliferation,
committed precursors differentiate to become either cell type. Studies have shown that
the transcription factor PU.1 is critical for the initial commitment or determination phase:
Its deletion results in osteopetrosis without either osteoclasts or macrophages (Tondravi,
McKercher et al. 1997).
1.2.2 Regulation of Osteoclastogenesis
Under a series of regulations, hematopoietic stem cells experience several
processes, including proliferation, differentiation, fusion, and activation, and become
functional active osteoclasts (Figure 1.5). The active osteoclasts eventually have the
capability to resorb bone. Breakthroughs have occurred in this field during the past
decade and have increased people’s understanding in osteoclast biology. It is now clear
that cells required for in vitro osteoclast culture, osteoblasts and stromal cells, express
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two essential molecules that are necessary and sufficient to promote osteoclastogenesis:
macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear kappa B
(RANK) ligand (RANKL) (Teitelbaum 2000). In vitro osteoclast development could be
achieved by pure macrophages exposed to M-CSF and RANKL (Lacey, Timms et al.
1998), indicating the indispensable role of osteoblasts/stromal cells in osteoclastogenesis
through the release of these two cytokines. Different numbers and activities of osteoclasts
can be modulated by varying the concentrations and ratio of these two proteins in the
culture media (Lacey, Tan et al. 2000).
M-CSF
RANKL

M-CSF

PU-1

Multinucleated
Osteoclast

Preosteoclast

CFU-GM
Proliferation &
Differentiation

RANKL

Survival &
Fusion

Activated
Osteoclast
Activation

Figure 1.5 Osteoclastogenesis regulation. The transcription factor PU.1 is critical for the initial
commitment or determination phase. M-CSF is necessary for proliferation and differentiation, as
well as the survival of osteoclast progenitors. RANKL is the key regulator for the latter stages,
primarily the fusion of preosteoclasts and the final activation phase.

M-CSF is a cytokine expressed by osteoblasts and stromal cells. It binds to its
receptor c-fms

on early osteoclast precursors, thus stimulating early stage

osteoclastogenesis, particularly proliferation and differentiation (Kodama, Nose et al.
1991; Corboz, Cecchini et al. 1992; Felix, Halasy-Nagy et al. 1996). The important role
of M-CSF in osteoclastogenesis has been confirmed in vivo using M-CSF-deficient
osteopetrotic (op/op) mice: Mice with a specific knock-out of the M-CSF gene developed
profound osteopetrotic phenotype with little or no osteoclast activity (WiktorJedrzejczak, Bartocci et al. 1990; Yoshida, Hayashi et al. 1990). Subsequent studies
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showed that systemic administration of recombinant human M-CSF to op/op mice
increased the number of osteoclasts and led to partial or complete resolution of the
osteopetrotic defect (Kodama, Yamasaki et al. 1991; Sundquist, Jackson et al. 1995;
Abboud, Woodruff et al. 2002). However, no evidence was found that indicate M-CSF
plays a role in the activation phase of osteoclastogenesis. In contrast, a few studies
indicated that high concentration of M-CSF could potentially inhibit osteoclast activity
by inhibiting osteoclast activation (Perkins and Kling 1995; Abboud, Ghosh-Choudhury
et al. 2003). Detailed mechanisms of M-CSF will be discussed later in this chapter.
RANKL was discovered in 1998 and has been proven to be an important mediator
for osteoclastogenesis, which stimulates the latter stages of osteoclastogenesis: fusion,
survival, and activation (Figure 1.5). RANKL binds to its receptor RANK on the surface
of osteoclasts and their precursors, stimulates the activation of pre-osteoclasts to
functionally mature osteoclasts, and induces bone resorption (Lacey, Timms et al. 1998;
Yasuda, Shima et al. 1998). Osteoprotegerin (OPG) is the decoy receptor for RANKL. It
competes with RANK for the binding of RANKL, therefore decreasing RANKL-RANK
interaction and inhibiting bone resorption (Simonet, Lacey et al. 1997; Tsuda, Goto et al.
1997). Transgenic mice over-expressing RANKL, and OPG-knockout mice (OPG-/-)
developed severe osteoporosis symptoms including increased osteoclast numbers and
activities, low bone-mineral density, and high bone turnover (Kostenuik and Shalhoub
2001; Mizuno, Kanno et al. 2002). Detailed mechanisms of RANKL/OPG and their roles
in osteoclastogenesis will be discussed in the next section.
M-CSF and RANKL do not function alone to regulate osteoclastogenesis. Certain
hormones and cytokines produced in distant organs can also influence osteoclastogenesis
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(Figure 1.6). It has been shown that pro-resorptive factors, including tumor necrosis
factor α (TNF-α), interleukin 1β (IL-1β), interleukin 6 (IL-6), 1,25(OH)2 vitamin D3,
prostaglandin E2 (PGE2), parathyroid hormone (PTH), and PTH-related peptide
(PHTrP), can upregulate RANKL expression by osteoblasts, consequently stimulating
osteoclastogenesis and inducing bone resorption (Udagawa, Takahashi et al. 2000;
Schoppet, Preissner et al. 2002). On the other hand, antiresorptive factors can inhibit
osteoclastogenesis by decreasing RANKL expression or increasing OPG release. This
category of factors includes calcitonin, oetrogens, transforming growth factor β (TGF-β),
TPO, IL-17, interferon γ (INF-γ), and Platelet-derived growth factor (PDGF)
(Nakashima, Kobayashi et al. 2000; Boyle, Simonet et al. 2003).
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Figure 1.6 Hormonal regulations systems on osteoclastogenesis (Boyle, Simonet et al. 2003).
PTH: Parathyroid hormone; PTHrP: PTH related peptide; PGE2: Prostaglandin E2; IL:
Interleukin; TNF: Tumor necrosis factor; LIF: Leukemia inhibitory factor; BMP: Bone
morphogenetic protein; TGF-β: Transforming growth factor β; TPO: Thrombopoietin; PDGF:
Platelet-derived growth factor.
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1.3 RANK/RANKL/OPG System
Over the past two decades, the largest breakthroughs in bone biology have been
triggered by the identification and characterization of the RANK/RANKL/OPG system
(Simonet, Lacey et al. 1997; Tsuda, Goto et al. 1997; Lacey, Timms et al. 1998; Yasuda,
Shima et al. 1998).
As first noted in 1990, preosteoblasts and stromal cells regulate osteoclast
differentiation both by producing soluble factors and signaling to osteoclast progenitors
through cell-cell interaction (Udagawa, Takahashi et al. 1990; Suda, Takahashi et al.
1992). However, the critical factor produced by these cells mediating osteoclastogenesis
remained unknown for the next several years; bone biologists performed searches trying
to identify this mediator, and finally in 1997 and 1998, the identification of
RANK/RANKL/OPG system as the critical and final mediator of osteoclastogenesis
ended this obscurity (Simonet, Lacey et al. 1997; Tsuda, Goto et al. 1997; Lacey, Timms
et al. 1998; Yasuda, Shima et al. 1998). Osteoprotegerin (OPG) was first identified as a
TNF superfamily soluble member that inhibits osteoclastogenesis (Simonet, Lacey et al.
1997). Overexpression of OPG in the livers of transgenic mice resulted in osteopetrosis
(Simonet, Lacey et al. 1997); in contrast, disruption of the OPG gene (OPG-/- mice)
produced a high bone turnover osteoporotic phenotype (Bucay, Sarosi et al. 1998).
Subsequently, RANKL was identified to be the molecule, present in both membranebound and soluble forms, that was blocked by OPG and functions as the key mediator of
osteoclastogenesis (Lacey, Timms et al. 1998; Yasuda, Shima et al. 1998). These seminal
papers have initiated numerous studies on the RANK/RANKL/OPG system.
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1.3.1 Osteoprotegerin
OPG is a glycoprotein secreted by osteoblasts and stromal cells in the bone
microenvironment

and

binds

to

RANKL

as

a

decoy

receptor

inhibiting

osteoclastogenesis. OPG was discovered in 1997 by two groups in two different ways
(Simonet, Lacey et al. 1997; Tsuda, Goto et al. 1997). In a project focused on identifying
TNF receptor-related molecules that potentially have therapeutic utility, the Amgen Inc.
group found a particular cDNA in the rat intestine. Overexpression of this gene in a
mouse resulted in an osteopetrotic phenotype accompanied by a profound decrease in
osteoclasts (Simonet, Lacey et al. 1997). Later studies found that transgenic mice with
OPG gene knockout showed less bone mineral density and other severe osteoporosis
symptoms (Mizuno, Amizuka et al. 1998) (Figure 1.7). This study first discovered OPG
and indicated that it plays an important role in osteoclastogenesis. A month later, the
Snow Brand Milk Group in Japan reported a novel cytokine from the conditioned
medium of human embryonic lung fibroblasts cultures that inhibited osteoclastogenesis
(Tsuda, Goto et al. 1997). This factor, termed osteoclastogenesis inhibitory factor
(OCIF), later proved to be identical to OPG (Yasuda, Shima et al. 1998).
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Figure 1.7 Transgenic mice with OPG knockout showed severe osteoporosis symptoms (Mizuno,
Amizuka et al. 1998).

In contrast to other TNF receptor superfamily members, OPG lacks
transmembrane and cytoplasmic domains and is therefore secreted as a soluble protein
with 380 amino acids. OPG mRNA is expressed in many tissues, including bone, lung,
heart, kidney, liver, stomach, intestine, brain spinal cord, and thyroid gland (Simonet,
Lacey et al. 1997; Yasuda, Shima et al. 1998). In addition to severe osteoporosis, mice
with the OPG gene knock-out also developed calcification in large aortas (Bucay, Sarosi
et al. 1998; Mizuno, Amizuka et al. 1998); studies have shown that OPG may be
important for the survival of endothelial cells (Malyankar, Scatena et al. 2000). These
findings indicate that the RANK/RANKL/OPG system might be involved in the
regulation mechanism of the cardiovascular system. For this reason, vascular calcification
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induced by RANKL was examined in an in vivo study of this project (see Chapter 4 for
details).
1.3.2 RANKL and RANK
RANKL was identified by both Amgen and the Snow Brand Milk Group using
expression cloning with OPG as a probe, this time with the Japanese group reporting their
results first (Lacey, Timms et al. 1998; Yasuda, Shima et al. 1998). This protein was
initially termed OPG ligand (OPGL) and osteoclast differentiation factor (ODF), which
later turned out to be identical with two previous known members of the TNF ligand
family: TNF-related activation induced cytokine (TRANCE) and RANKL, a factor
known to stimulate dendritic cells (Anderson, Maraskovsky et al. 1997; Wong, Rho et al.
1997). This protein was eventually termed RANKL.
RANKL is a 317-amino acid family peptide that belongs to the TNF superfamily
of cytokines. RANKL exists in two forms: a 40- to 45-kDa membrane-bound form and a
31kDa soluble form derived by cleavage of the full-length form at position 140 or 145
(Lacey, Timms et al. 1998). RANKL mRNA is expressed in various tissues, with highest
levels in bone and bone marrow, as well as in lymphoid tissues (Anderson, Maraskovsky
et al. 1997; Wong, Rho et al. 1997; Lacey, Timms et al. 1998; Yasuda, Shima et al.
1998). Although RANKL was originally identified as a dendritic cell survival factor
produced by activated T cells, subsequent studies have established the role of RANKL
being the primary mediator and final effector of osteoclastogenesis. Its role and
importance to the immune system is still being identified, while its critical role in
osteoclastogenesis is established (Figure 1.8).
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Figure 1.8 Mechanism of action of RANKL (Amgen Inc., Thousand oaks, CA). OB: Osteoblast;
CFU-M: Colony forming unit- macrophage.

RANK, the receptor of RANKL, belongs to the TNF receptor superfamily
(Anderson, Maraskovsky et al. 1997). RANK mRNA is highly expressed in osteoclast
progenitors and mature osteoclasts (Hsu, Lacey et al. 1999). RANK knock-out transgenic
mice showed profound osteopetrosis due to the lack of osteoclasts (Li, Sarosi et al. 2000),
demonstrating RANK as the sole receptor for RANKL during osteoclastogenesis.
RANKL interacts with the RANK receptor to recruit TNF receptor–associated factor 6
(TRAF-6), a member of TNF family signal transducers (Theill, Boyle et al. 2002).
TRAF-6 binds to one or more of four binding sites in the intracellular domain of the
RANK receptor and then signals downstream through several signaling cascades, most
notably those involving NF-κB, mitogen-activated protein (MAP) kinases (extracellular

24
signal-regulated kinase [Erk], Janus N-terminal kinase [JNK], and p38), and Akt-2
(Theill, Boyle et al. 2002).
1.3.3 RANK/RANKL/OPG System in Skeletal Diseases
The RANKL to OPG ratio has been suggested to represent a potentially important
determinant of bone remodeling, and an increased RANKL:OPG ratio is evident in
various bone diseases (Blair, Zhou et al. 2006). These disorders range from traditional
causes for osteoporosis to localized inflammatory conditions leading to osteolysis and
include cancer, particularly when metastasized to bone.
Estrogen deprivation in postmenopausal women stimulates the production of a
variety of regulatory cytokines, such as IL-1β, IL-6, TNF-α, and M-CSF, which promote
RANKL production and stimulate osteoclast formation and activation (Suda, Takahashi
et al. 1999; Eghbali-Fatourechi, Khosla et al. 2003). In a study targeting postmenopausal
osteoporosis patients, RANKL concentration was shown to correlate with the bone
resorption markers, serum C-terminal telopeptide and urine N-telopeptide of type I
collagen, indicating RANKL as the final effector of osteoclastogenesis (EghbaliFatourechi, Khosla et al. 2003).
In an inflammatory environment, such as in rheumatoid arthritis, cytokines
released by the immune cells (IL-1, TNF-α, IL-6) increase the RANKL:OPG ratio and
lead to joint destruction and bone loss (Kong, Feige et al. 1999; Lubberts, van den
Bersselaar et al. 2003; Stolina, Adamu et al. 2005). Additionally, RANKL also plays an
important role in malignant diseases, such as multiple myeloma and osteolytic bone
metastases. Myeloma cells enhance RANKL release and down-regulate OPG expression,
thereby increasing bone resorption while inhibiting bone formation, which uncouples
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bone remodeling and leads to accelerated bone loss (Giuliani, Bataille et al. 2001;
Standal, Seidel et al. 2002). In osteolytic bone metastases, such as breast and lung cancer,
tumor cells directly express RANKL and/or indirectly increase RANKL levels through
expression of PTH related peptide (PTHrP), resulting in bone lesions (Michigami, IharaWatanabe et al. 2001; Mundy 2002).
1.4 Macrophage Colony Stimulating Factor
As a known key regulator for the proliferation and differentiation stages of
osteoclastogenesis, M-CSF (also known as colony stimulating factor-I [CSF-I]) was
originally defined by its ability to stimulate the preferential growth of macrophage
colonies from bone marrow precursors (Stanley, Guilbert et al. 1983). Subsequent studies
found that M-CSF is a haematopoietic growth factor that stimulates the survival,
proliferation, differentiation and functions of cells from the mononuclear phagocytic
lineage (Rettenmier and Sherr 1989) (Figure 1.9). M-CSF is primarily produced by
connective tissue cells (including osteoblasts) and exists in both soluble and membranebound forms. The membrane-bound form is expressed as an integral transmembrane
glycoprotein, whereas the soluble form is rapidly secreted into the circulation as a
glycoprotein or chondroitin sulfate-containing proteoglycan. Both isoforms act on the
target cells through a specific cell surface tyrosine kinase receptor encoded by the c-fms
proto-oncogene. M-CSF receptor (CSF-1R) contains an extracellular ligand-binding
domain, a transmembrane domain, and an intracellular tyrosine domain. M-CSF is a
disulfide-linked homodimer that, by binding to CSF-1R, stabilizes CSF-1R dimerization
to activate the receptor through autophosphorylation, thereby initiating a series of
membrane-proximal tyrosine phosphorylation cascades, leading to rapid stimulation of
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cytoskeletal remodeling, gene transcription, and protein translation (Yeung and Stanley
2003).

Figure 1.9 M-CSF action in bone and other tissues. M-CSF (CSF-1) synergizes with
hematopoietic growth factors (HGFs) to generate mononuclear progenitor cells from multipotent
progenitors, and with RANKL to generate osteoclasts from mononuclear phagocytes. Red arrows
indicate cell differentiation steps; blue arrows indicate cytokine regulation (Pixley and Stanley
2004).

1.4.1 The Central Role of M-CSF in Osteoclastogenesis
Numerous in vitro and in vivo studies have been done to prove that M-CSF is a
critical regulator of osteoclastogenesis. Takahashi et al. demonstrated that M-CSF is
central for the proliferation of osteoclast progenitors derived from committed
granulocyte-macrophage progenitors (CFU-GM) (Takahashi, Udagawa et al. 1991).
Pretreatment of bone marrow cells with M-CSF in the culture media for 6 days before
incubation with normal osteoblasts resulted in the formation of numerous osteoclast-like
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multinucleated cells in the presence of vitamin D3. Subsequently, Tanaka et al.
demonstrated that M-CSF was required for both the proliferation and differentiation of
osteoclast progenitors (Tanaka, Takahashi et al. 1993). Spleen cells are a source of
osteoclasts; when co-cultured with mouse osteoblasts and incubated with either anti-MCSF or c-fms antibody during the proliferation and differentiation phases, osteoclast
formation that was induced by 1,25(OH)3D3 was inhibited. The ability of M-CSF to
stimulate osteoclast development and function in vivo has been confirmed using the MCSF deficient osteopetrotic (op/op) mouse model (Wiktor-Jedrzejczak, Bartocci et al.
1990; Yoshida, Hayashi et al. 1990). Systemic administration of recombinant human
soluble M-CSF to op/op mice had been shown to increase the number of osteoclasts and
led to partial or complete resolution of the osteopetrotic defect (Kodama, Yamasaki et al.
1991; Wiktor-Jedrzejczak, Urbanowska et al. 1991; Sundquist, Cecchini et al. 1995).
1.4.2 The Antiresorptive Potential of M-CSF
The action of M-CSF on bone is complex. Though being a potent promoter of
osteoclast proliferation and differentiation, M-CSF inhibits mature osteoclasts activity
thus decreasing bone resorption. In a study using ST-2 stromal cell and murine bone
marrow coculture, exogenous M-CSF caused a 98% dose-dependent decrease in tartrateresistant acid phosphatase (TRAP) positive multinucleated cells (Perkins and Kling
1995). In studies using isolated mature rat osteoclasts, Hattersley et al. demonstrated that
M-CSF, though enhanced osteoclast survival by preventing apoptosis, acted as a
chemotactic agent and inhibited bone resorption (Hattersley, Dorey et al. 1988; Fuller,
Owens et al. 1993). In vivo, transgenic mice selectively over-expressed soluble M-CSF in
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bone and showed increased cortical thickness in the femoral diaphysis caused by new
bone formation along the endocortical surface (Abboud, Ghosh-Choudhury et al. 2003).
As a summary, these findings indicated that M-CSF is a key determinant for
osteoclastogenesis both in vitro and in vivo. M-CSF exhibits bi-polar effects: it promotes
osteoclast proliferation and differentiation while inhibiting osteoclast activation.
However, the precise biological effects of M-CSF on bone formation, geometry,
structure, and bone biomechanics remain unclear. Therefore, we performed in vivo
studies with M-CSF to explore these unknown effects on bone biomechanics. Details will
be presented in Chapter 5 of this project.
1.5 Skeletal Diseases
Under most conditions, osteoblast and osteoclast activities are closely coupled: a
direct increase or decrease in the activity level of one cell type will lead to an indirect
change in the other cell type in the same direction through cytokine signaling. There are,
however, some skeletal pathologies characterized by uncoupled osteoclast and osteoblast
activity, mostly exhibiting excessive osteoclast activity. This excessive osteolysis is an
important clinical problem in many common lesions, including osteoporosis, cancer
metastases in bone, inflammatory joint diseases, and implanted joint prosthesis failure.
The following paragraphs will focus on osteoporosis and malignant bone metastases,
which are the most common osteolytic diseases triggered by the abnormally activated
osteoclasts.
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1.5.1 Osteoporosis
Osteoporosis is currently defined as a systemic skeletal disorder characterized by
low bone mass and bone microarchitecture deterioration (Figure 1.10), with a consequent
increase in bone fragility and susceptibility to fracture (Consensus Development
Conference, 1993). Clinically, osteoporosis is recognized by the occurrence of
characteristic low trauma fractures, which typically arise at the hip, spine, and wrist. It is
also a disease that increases in severity with age of the patient. The clinical diagnosis of
osteoporosis is made if a bone densitometry scan demonstrates a bone mineral density
(BMD) that is 2.5 standard deviations below the mean peak bone mass of young adult.
Osteopenia (‘at risk’, low bone mass) is defined at BMD 1.0 standard deviations below
normal (National Osteoporosis Foundation, www.nof.org).
Osteoporosis is a major public health problem. According to the International
Osteoporosis Foundation, osteoporosis affects an estimated 75 million people in Europe,
USA and Japan. Overall 30%-50% women and 15%-30% of men will suffer a fracture
related to osteoporosis in their lifetime. Because hip fracture incidence rates increase
exponentially with age, the number of hip fractures worldwide will rise from 1.3 million
in 1990 to an estimated 2.3 million in 2020 (L Joseph Melton, et al. 2004). Treatments for
osteoporosis related fractures are normally invasive surgeries, such as hip replacement.
This substantial number of hip surgeries, in addition to the other fractures associated with
osteoporosis, could have a devastating effect on patient costs and quality of life for the
elderly population.
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Figure 1.10. Normal (left) and osteoporotic (right) human trabecular bone (Marx 2004).

1.5.1.1 Mechanism of Osteoporosis
Osteoporosis can be triggered by many factors, such as menopause,
glucocorticoid therapies, and aging. Among these factors, estrogen deficiency in
menopausal states is the most common cause. Estrogen is an important regulator of bone
remodeling; it protects against bone loss. Studies have shown that estrogen deficiency is
the cause of both the early and the late forms of osteoporosis in post-menopausal women
and contributes to the development of osteoporosis in aging men (Khosla, Melton et al.
2002; Riggs, Khosla et al. 2002). Estrogen deficiency is associated with an increase in
bone resorption over bone formation, leading to excessive and sustained bone loss. The
increase in bone resorption is due both to increased osteoclastogenesis and to decreased
osteoclast apoptosis (Manolagas 2000). The mechanism of estrogen deficiency induced
bone loss, though not fully understood, is largely related to the RANK/RANKL/OPG
system by increasing RANKL/OPG ratio.
Studies have shown that estrogen deprivation in postmenopausal women led to
increased production of a variety of regulatory cytokines, such as IL-1β, IL-6, TNF-α and
M-CSF, which boost RANKL production and thus osteoclast formation and activation
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(Suda, Takahashi et al. 1999; Eghbali-Fatourechi, Khosla et al. 2003). In a study using
fluorescent-activated cell sorting to isolate osteoblast precursor cells from premenopausal
women, women in early menopause without any treatment, and estrogen-treated
postmenopausal women, researchers found that the cells from the untreated
postmenopausal women carried much higher levels of RANKL than those from the
women in the other two groups (Eghbali-Fatourechi, Khosla et al. 2003). In this study,
the RANKL concentration also correlated with the bone resorption markers serum Cterminal telopeptide and urine N-telopeptide of type I collagen, indicating RANKL as the
final effector of osteoclastogenesis (Eghbali-Fatourechi, Khosla et al. 2003). By upregulating RANKL production, estrogen deficiency has several functional effects,
including:

increased bone turnover rates, deep resorption cavities, trabecular plate

perforation, wide separation and disconnection of trabeculae, and enlargement and
coalescence of sub-endocortical spaces.
Besides estrogen deficiency, incidence of osteoporosis increases with age. In
aging skeletons, the number of osteoblasts that are recruited to erosion surfaces and
osteoblast functional activity are decreased, resulting in a decreased rate of bone
formation. Estrogen deficiency also suppresses survival of osteocytes and impairs the
response of osteoblasts to mechanical stimuli and detection of microdamage, and
therefore the repair of aged bone (Manolagas 2000). With increasing age in women as
well as in men, microdamage accumulates more rapidly than intrinsic processes can
repair, resulting in microarchitectural deterioration and decreased bone strength
(Schaffler, Choi et al. 1995).
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1.5.1.2 Osteoporosis Therapies
Current therapies for osteoporosis can be classified to two major categories:
antiresorptive and anabolic. Antiresorptive therapies target osteoclasts, either decreasing
osteoclastogenesis or increasing osteoclast apoptosis. Over the past decades, most
osteoporosis patients have been treated with antiresorptive agents such as estrogen and
bisphosphonates. Researchers have long known that estrogen deficiency is the major
cause of osteoporosis, however, the most obvious therapeutic strategy, hormone
replacement therapy (HRT), had been implicated in increasing the risk of both breast
cancer and cardiovascular diseases (Couzin 2003). Therefore antiresorptive therapies,
namely bisphosphonates, have been used most extensively due to their safety and potent
efficacies on inhibiting bone resorption.
Bisphosphonates are a class of pyrophosphate analogues that bind with high
affinity to the hydroxyapatite bone matrix, internalized by osteoclasts through
endocytosis during bone resorption (Coxon, Thompson et al. 2006). This internalization
leads to osteoclast apoptosis by inhibition of farnesyl diphosphate synthase, a key
enzyme of the mevalonate pathway (Coxon, Thompson et al. 2006). Several
bisphosphonates have been approved by FDA for treatment of osteoporosis, including as
alendronate (ALN), risedronate (RIS), zoledronate (ZLN), and ibandronate (IBN)
(Chapurlat and Delmas 2006). Clinical use of these drugs has been shown to improve
patients’ bone mineral density, trabecular bone connectivity and decrease the risk of
fracture. However, due to the coupling of bone resorption and bone formation,
bisphosphonates can inhibit or reduce bone formation. After binding with bone matrix,
bisphosphonate molecules can remain in the skeletal system for many years.
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Accumulation of bisphosphonates due to long-term therapies can potentially oversuppress bone turnover, impairing bone’s natural recovering ability and increasing
fracture risk (Rodan, Reszka et al. 2004).
Recombinant human parathyroid hormone (rhPTH, I-34) was approved by FDA
in 2002 as an anabolic agent to treat osteoporosis through stimulating new bone growth.
This anabolic bone-active agent stimulates osteoclasts to form new bone, primarily by
stimulating new formation on quiescent bone surface that is not simultaneously
undergoing remodeling. In a large clinical trial performed by Neer and colleagues,
postmenopausal women patients receiving rhPTH increased BMD by 9-13% in the
lumbar spine and 3% in the femoral neck (Neer, Arnaud et al. 2001). The anabolic effects
of rhPTH have been demonstrated to be most pronounced in the trabecular bone,
evidenced by increased trabecular number and connectivity (Dempster, Cosman et al.
2001). Compared to the patients receiving placebo control, risk of new vertebral fractures
was reduced by 65% and nonvertebral fractures reduced by 35% (Neer, Arnaud et al.
2001). However, rhPTH is not an ideal treatment for osteoporosis. First, compare to the
common weekly oral doses of bisphosphonates, it requires daily injection, which is
inconvenient and limits compliance. Second, rhPTH injection also stimulates the
production of osteoclast stimulating cytokines, primary RANKL and IL-6, thus
increasing bone resorption simultaneously with bone formation and partly counteracts its
positive effects on bone strength (Fu, Jilka et al. 2002). Furthermore, as an anabolic
agent, rhPTH can potentially stimulate the growth of tumor cells and increase the risk of
tumor incidence and metastasis. Therefore, to limit the risk of tumor initiation, current
rhPTH therapy was approved for use for a maximum of two years.
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In recent years, many studies have shown great potential in using
RANK/RANKL/OPG system as a therapeutic target for osteoporosis. Strategies include:
suppression of RANKL expression using 17 β-estradiol (Eghbali-Fatourechi, Khosla et
al. 2003); RANKL blockage by soluble RANK fusion proteins, OPG fusion proteins, or
RANKL antibodies (Min, Morony et al. 2000; Oyajobi, Anderson et al. 2001; Bekker,
Holloway et al. 2004); and stimulation of OPG production (Onyia, Galvin et al. 2004). A
clinical trial reported that a single dose of AMG 162, a RANKL antibody developed by
Amgen (Thousand Oaks, CA), decreased bone resorption for up to 6 months when given
to postmenopausal women. The drugs effect in blocking bone resorption was at least
comparable to bisphosphonates (Bekker, Holloway et al. 2004).
1.5.2 Osteolytic Bone Metastasis
Cancerous cells can remain in the particular organ of origin (primary cancer) or
metastasize to other organs and tissues (metastatic cancer). Due to the highly
vascularized structure and the cytokine and growth factor environment, the skeleton is the
most common organ to be affected by metastatic cancer. Common tumors, such as breast,
lung, and prostate frequently metastasize to bone. Bone metastases are often classified as
either osteolytic or osteoblastic. The majority of malignant bone metastases are
osteolytic, including breast and lung cancer, as well as those bone lesions found in
multiple myeloma. These osteolytic bone metastases can result in severe bone pain,
decreased bone mineral density, reduced bone strength, pathological fractures, and
hypercalcemia (Mundy 2002; Blair, Zhou et al. 2006). On the other hand, prostate cancer
bone metastases, as well as some other bone metastases, are osteoblastic. In these lesions,
excess bone tissue is deposited in a disorganized woven structure, bones are weak and
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pathological fractures frequently occur (Mundy 2002; Blair, Zhou et al. 2006). Due to the
coupling between bone resorption and bone formation, there is no absolute osteolytic or
osteoblastic cancers, most bone metastases show mixed patterns with the dominant lesion
being osteolytic or osteoblastic, symptoms of the other lesion are usually evident.
Osteolytic bone metastases induce abnormalities in bone remodeling primarily through
stimulations on osteoclastogenesis. Studies have indicated that RANK/RANKL/OPG
systems play an important role in this regulation process.
1.5.2.1 Mechanisms of Osteolytic Metastases
Among many regulation factors, PTH related peptide (PTHrP) is a key mediator
of bone destruction in osteolytic cancers (Southby, Kissin et al. 1990; Powell, Southby et
al. 1991; Miki, Yano et al. 2000; Bryden, Hoyland et al. 2002). It is well known that
osteolytic breast cancer tumor cells can express PTHrP in vivo. Previous studies also
show that PTHrP expression is greater when the tumor cells metastasize to bone than
when they are present in soft tissue sites or in the breast (Southby, Kissin et al. 1990;
Powell, Southby et al. 1991). In the bone microenvironment, the overproduction of
PTHrP, as well as cytokines such as IL-1 and IL-6, stimulates osteoclast activity by
stimulating RANKL production by osteoblasts and stromal cells. RANKL binds to
RANK and triggers the intracellular signal transduction, leading to differentiation of
osteoclast progenitors into mature osteoclasts (Figure 1.11). Moreover, PTHrP can
decrease the production of OPG, thus further increasing the RANKL/OPG ratio. Some
researchers also reported that RANKL can be released directly by the tumor cells that
migrated to the bone microenvironment (Zhang, Dai et al. 2001).
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Figure 1.11 The RANK/RANKL/OPG system in osteolytic bone metastases. Cytokines such as
PTH or PTH-related peptide, interleukin (IL)-1, IL-6 and IL-11 stimulate production of RANKL
by osteoblasts and stromal cells. Signaling through RANK in osteoclast progenitors activates
transcription factors such as AP1 (activated by JUN N-terminal kinase (JNK), or JUN) and NFκB (activated by inhibitor of κB kinase (IKK)), leading to the differentiation of osteoclast
progenitors into mature osteoclasts. These osteoclasts mediate bone resorption (Mundy 2002).

Interaction between tumor cells and osteoclasts not only cause osteolytic bone
destruction, but may also contribute to tumor proliferation. Active growth factors
released during bone resorption, including primary insulin-like growth factor 1 (IGF-1)
and TGF-β, together with the elevated extracellular calcium concentrations, can stimulate
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the differentiation and growth of tumor cells (Yin, Selander et al. 1999; Yu and Rohan
2000). The increased number and activity of tumor cells thus release more PTHrP into
the bone microenvironment, inducing bone destruction through stimulating RANKL
expression. Increased RANKL will result in an increase in active growth factors levels
via increased resorption, thus further stimulating tumor cell growth. Therefore, a vicious
cycle exists in the mechanism pathway of osteolytic metastases (Figure 1.12). This cycle
supports the growth of tumor cells metastasized to bone and their interrelations with bone
remodeling, further contributing to the high frequency of the skeleton as a cancer
metastatic site.

Figure 1.12 The cycle of osteolytic metastases not only cause bone destruction, but also initiates
a feedback loop that promotes tumor proliferation and therefore additional bone destruction
(Mundy 2002).
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1.5.2.2 Therapeutic Approaches
Currently, bisphosphonates are widely used to treat osteolytic bone metastases
through inhibiting bone resorption. These antiresorptive agents can interrupt the cycle by
stimulating osteoclast apoptosis, thus decreasing the bone tumor burden and stimulating
tumor cell apoptosis (Diel, Solomayer et al. 1998; Powles 1999). Recent studies show
that the new generation of bone resorption inhibitors, such as OPG and RANKL antibody
(AMG 162) which directly targets RANKL, might be more effective than
bisphosphonates (Oyajobi, Anderson et al. 2001). Clinical studies have shown that OPG
causes a rapid, sustained, dose-dependent decrease in bone resorption marker levels in
multiple myeloma and breast cancer patients (Body, Greipp et al. 2003; Body, Facon et
al. 2006).
1.5.3 Animal Models for Skeletal Diseases
Laboratory animals have played a major role in the enhanced understanding of
skeletal diseases. Animals contributed to the knowledge of the etiology of osteoporosis
and are essential for the preclinical evaluation of efficacy and safety in the discovery of
therapies. The goal of setting up an animal model is to successfully predict an outcome in
humans. However, perfect models for any disease rarely exist; weaknesses are present in
each well-established model currently being used for skeletal disorders.
Because of the low costs, fast growth, and the well-characterized skeletons, rats
have historically been used as the most used laboratory animal for studies of
osteoporosis. A study performed in 1985 observed that acute ovarian estrogen deficiency
leads to dramatically increased cancellous bone turnover (Wronski, Lowry et al. 1985).
Subsequent studies showed that ovariectomy (OVX) resulted in cortical and trabecular
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bone loss, leading to the wide adoption of this model (Turner, Riggs et al. 1994). OVX
rats trigger a series of cytokine reactions that mimic the postmenopausal status, thus
stimulate bone resorption and lead to bone loss. Detailed mechanisms of estrogen
deficiency had been described earlier (1.5.1.1 Mechanism of osteoporosis). However, the
OVX model requires a complicated surgical procedure on each subject, which increases
the cost and limits the practicality of this model. Besides the OVX models, rats had been
also used as a model for disuse osteoporosis, which could be induced by unilateral sciatic
nerve damage, tendonotomy, unilateral limb casting, hindlimb suspension or spaceflight
(Morey and Baylink 1978; Turner and Bell 1986; Bateman, Zimmerman et al. 1998). All
disuse models require surgery or other complicated procedures.
Recent

improvements

on

transgenic

technology

allow

the

purposeful

manipulation of targeted gene expression, which had made mice another popular model
for skeletal diseases. Many studies had used the techniques of specific knock-out or overexpression of targeted genes in transgenic mice and greatly improved understanding of
the mechanisms of bone remodeling and skeletal diseases. The roles of a series of key
regulators in the skeletal system, such as M-CSF, RANKL, OPG, PTHrP, and PU-1, were
either discovered or confirmed using transgenic mice (Felix, Cecchini et al. 1990;
Lanske, Karaplis et al. 1996; Simonet, Lacey et al. 1997). However, drawbacks also exist
while use transgenic mice as a disease model: Genes being specifically knocked-out or
over-expressed are usually important in other systems besides the skeleton, thus many
growth defects accompanied the skeletal abnormality in transgenic mice, which makes it
difficult to mimic the pathological states. Furthermore, the development of a new
transgenic mice model usually takes a long period of time.
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Therefore, there is a need to develop novel animal models for skeletal diseases.
Due to the unique role and functions of RANK/RANKL/OPG system in
osteoclastogenesis, we have targeted RANKL, the final effector of osteoclastogenesis, as
a specific agent for developing novel bone loss models. Study details will be presented in
Chapter 4 of this project.
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CHAPTER 2
PROJECT RATIONALE
2.1 General Hypothesis
As described in detail in Chapter One, previous studies have demonstrated the
important role of M-CSF and RANKL on osteoclastgenesis. M-CSF stimulates the
proliferation and early differentiation of osteoclast progenitors to osteoclast lineage,
while RANKL targets the later stages of fusion and activation, and stimulates the
formation of functional active osteoclasts (Figure 2.1). In this project, we hypothesized
that while M-CSF and RANKL can both stimulate osteoclastogenesis, the
differences in activation stages targeted by these two cytokines would result in
distinct responses on bone biomechanics. RANKL would act as the final effector of
osteoclastogenesis by directly stimulating osteoclast activity and increasing bone
resorption. Alternately, M-CSF promotes the proliferation and differentiation of
osteoclast progenitors but not the activation of mature osteoclasts, thus it has less
influence on bone resorption but stimulates osteoblast development through the coupling
of osteoclast-osteoblast cells, and may promote bone formation and increase bone
biomechanical properties.
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2.2 Specific Aims
Aim 1: Examine the basic functional and biomechanical effects of RANKL
administration on mouse bone density and quality. Hypothesis: Artificial RANKL
administration is destructive to bone biomechanics. Approach: Mice received two
different dosages of RANKL by twice daily injections for 10 days. Femora and tibiae
were collected at sacrifice. Cortical and trabecular bone volume, bone mineral content,
bone strength, and bone turnover markers were analyzed to evaluate the functional
changes on bone induced by direct soluble RANKL injection. These experimental results
are presented in Chapter 3.

Aim 2: Develop a RANKL-induced bone destructive model for high-turnover
osteolytic bone diseases. Hypothesis: Continuous infusion of metabolically relevant
doses of RANKL in a mature rat model mimics deleterious skeletal changes in many
osteolytic skeletal diseases. Approach: Six-month old rats received long term (28 days)
RANKL infusion via osmotic pumps to create a skeletally mature bone loss model. Blood
was collected at predetermined time points to examine changes in bone turnover markers
rates by ELISA. Femurs and tibias were collected at sacrifice to evaluate the changes in
volume, mineral content, geometry and strength. Aortas were also collected to evaluate
the correlation of vascular calcification and RANKL induced bone loss. These
experimental results are presented in Chapter 4.
Aim 3: Characterize the effects of artificial M-CSF administration on the skeleton
and determine its potential as an anabolic agent for bone biomechanics. Hypothesis:
Activation of osteoclasts early in the differentiation cycle will have an anabolic, rather
than catabolic, effect on skeletal properties. Approach: High dosages M-CSF were
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administered to seven-week old mice for 3 weeks. Serum was collected at sacrifice to
examine bone turnover markers levels. Femora and tibias were collected to evaluate the
changes in volume, mineral content, geometry and strength. These experimental results
are presented in Chapter 5.
2.3 Clinical Significance
Many skeletal diseases, such as osteoporosis, malignant bone metastases, and
rheumatoid arthritis are generally osteolytic and associated with increased bone turnover
rates and bone remodeling towards excessive resorption. Equilibrium of the regulation
network is interrupted in these disease states, resulting in excessive osteoclast activity,
bone loss, inferior bone architecture, and increased fracture risk. Within the complex
cytokine environment, RANKL and M-CSF are critical for osteoclast differentiation and
activation. RANKL is the final effector of osteoclast activation and bone resorption.
Skeletal complications in osteolytic diseases are generally triggered by up-regulation of
RANKL expression levels in the bone local environment. M-CSF plays an indispensable
role in early osteoclast development. Mice with M-CSF gene knockout developed
profound osteoporosis-opposite (osteopetrotic) phenotype with little or no osteoclast
activity.
It is evident that both RANKL and M-CSF are necessary for osteoclastogenesis.
However, the impact of excessive levels of these two cytokines, resulting in activations
of osteoclastogenesis at different stages, has not been fully characterized. The goal of this
project is to further investigate the mechanism of critical cytokine regulation on
osteoclastogenesis and subsequent biomechanical changes. Studies in this project have
demonstrated the deleterious effects of elevated RANKL levels to bone biomechanics,
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and suggested a novel bone loss animal model induced by RANKL for osteolytic skeletal
disease research. Aim 3 of this project showed that M-CSF increased bone formation
through coupled stimulating early osteoclastogenesis and osteoblast development, and
indicated the potential of M-CSF as a novel anabolic agent for osteoporosis. Finally,
Chapter 6 presents the conclusions and recommendation for future work. Data from this
study could provide fundamental tools and information for future exploration on skeletal
diseases.
.

CHAPTER 3
EXAMINATION OF RANKL AS A CRITICAL OSTEOCLASTOGENESIS
STIMULATOR AND ITS FUNCTIONAL EFFECTS ON BONE DENSITY AND
QUALITY
Data related to this chapter has been submitted as a manuscript to Bone. Contents
presented here are the manuscript formatted following dissertation requirements.
3.1 Introduction
Bone strength is determined by bone mass and bone quality (Ammann and Rizzoli
2003; Heaney 2003). Bone mass reflects the balance between bone formation and bone
resorption, which involves regulation of osteoblast and osteoclast numbers and activity at
the cellular level. Moreover, bone formation and resorption is a coupled process:
osteoblasts regulate the recruitment and activity of osteoclasts through expression of
RANKL and OPG (Simonet, Lacey et al. 1997; Lacey, Timms et al. 1998). Balanced
RANKL/OPG levels are critical for maintaining bone remodeling in a precise manner
(Simonet, Lacey et al. 1997; Lacey, Timms et al. 1998; Hofbauer and Heufelder 2001;
Khosla 2001). Bone quality is determined by a number of variables, including bone
turnover, microarchitecture, microdamage, and degree of mineralization. Of these many
determinants of bone quality, bone turnover is particularly important. Unnecessarily high
bone turnover markedly degrades bone quality by disrupting the normal bone remodeling
cycle (Turner 2002; Heaney 2003). For example, Paget’s disease in humans is
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characterized by high bone turnover, rapid remodeling of woven bone, skeletal deformity,
and fractures (Roodman and Windle 2005).
RANKL (Receptor Activator of NF-κB Ligand), expressed by stromal cells and
osteoblasts, is an essential mediator of osteoclast formation, activation, and survival
(Lacey, Timms et al. 1998). RANKL binds to its receptor RANK on the surface of
osteoclasts and their precursors; stimulates differentiation of osteoclastic precursors into
mature osteoclasts; activates mature osteoclasts; and induces bone resorption (Lacey,
Timms et al. 1998; Suda, Takahashi et al. 1999; Takahashi, Udagawa et al. 1999; Lacey,
Tan et al. 2000). Osteoprotegerin (OPG), a member of the tumor necrosis factor-receptor
superfamily, is a soluble decoy receptor for the ligand and blocks RANKL/RANK
interactions (Simonet, Lacey et al. 1997; Kostenuik and Shalhoub 2001). Previous studies
confirm this important role of the RANKL/OPG system. Transgenic mice overexpressing
RANKL, and OPG-knockout mice (OPG-/-) each develop severe osteoporosis
accompanied by increased osteoclast differentiation and activation, low bone mineral
density, and high bone turnover (Lacey, Timms et al. 1998; Kostenuik and Shalhoub
2001; Mizuno, Kanno et al. 2002). As these studies indicate, the amount of bone resorbed
during the bone remodeling process is dictated by the balance between the expression of
RANKL and its inhibitor, OPG.
RANKL exists in both soluble and membrane-bound forms. Membrane-bound
RANKL has been found to be a member of membrane-associated tumor necrosis factor
family, expressed on the osteoblast/stromal cell surface (Lacey, Timms et al. 1998;
Hofbauer and Heufelder 2001). Membrane-bound RANKL mediates bone resorption by
binding to its receptor RANK through direct cell-to-cell interaction between osteoblasts

60
and osteoclasts (Yasuda, Shima et al. 1998). In cell co-culture systems, this cell-cell
interaction appears to be essential for osteoclastogenesis and activation (Yasuda, Shima
et al. 1998). However, soluble RANKL also induces osteoclastogenesis and bone
resorption in cell culture systems (Lacey, Timms et al. 1998). In addition to its
membrane-bound form, RANKL can be directly secreted from cells (Suzuki, Ikeda et al.
2004), and can also be released from the surface of activated T cells (Mizuno, Kanno et
al. 2002; Kanamaru, Iwai et al. 2004). Although previous in vitro studies suggest that
membrane-bound RANKL is more potent than the soluble form in osteoclastogenesis
development (Yasuda, Shima et al. 1998; Nakashima, Kobayashi et al. 2000), the
contribution of each form on regulation of bone remodeling remains largely unknown.
We hypothesized that the direct injection of soluble recombinant RANKL would
recapitulate many of the skeletal changes that have been described in mice that lack the
OPG gene, including deleterious effects on bone volume, geometry, density, and strength,
and serve as an accelerated model for high-turnover bone disease such as postmenopausal osteoporosis.
3.2 Materials and Methods
3.2.1 Study design
Thirty-six female C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) aged 10
weeks were assigned to one of three groups: VEH (placebo control, phosphate buffered
saline, n=12), LOW (0.4 mg/kg/day RANKL injection, n=12), HI (2 mg/kg/day RANKL
injection, n=12). The form of human RANKL used in all studies comprised amino acids
143-317, a region that includes the entire active ligand moiety distal to the extracellular
cleavage site, as previously described (Lacey, Timms et al. 1998). This construct, which
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lacks transmembrane and intracellular domains, was expressed in Chinese Hamster
Ovary (CHO) cells and purified at Amgen. The purified protein had a molecular weight
of 27 kD. All mice received twice daily subcutaneous injections (0.2ml per injection) for
10 days. Body weights were monitored every two days, and drug concentrations were
adjusted accordingly. Calcein (20 mg/kg) was injected (i.p.) as a fluorescent label at Day
2 to monitor new bone growth. At Day 10, animals were anesthetized with isoflurane and
euthanized by exsanguination followed by cervical dislocation. Both hind limbs were
removed and cleaned of all nonosseous tissue. All procedures performed throughout the
experiment conformed to the guidelines of Clemson University’s Institutional Animal
Care and Use Committee (Figure 3.1).
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Figure 3.1 Flowchart illustrating study design of the in vivo characterization of RANKL on bone
biomechanics.
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3.2.2 Serum bone-turnover markers
Serum was obtained at sacrifice, and markers for bone formation and resorption
were measured. Serum alkaline phosphatase (ALP) and total calcium levels were
measured by an automated chemistry analyzer (Hitachi) as markers of bone formation
and hypercalcemia, respectively. As a bone resorption marker, serum TRAP-5b was
measured by ELISA (SBA Science/IDS Inc.).
3.2.3 Micro CT
Microcomputed tomography analysis (µCT20, Scanco Medical AG, Bassersdorf,
Switzerland) with a voxel size of 9 µm in all three spatial dimensions was used to obtain
both cortical and trabecular parameters (Ruegsegger, Koller et al. 1996; Dufresne 1998).
Right femora were air-dried prior to the scan. Cortical bone parameters were obtained by
scanning an 8 mm section of the femoral diaphysis (Figure 3.2), the same span length
examined by mechanical testing. A total of 81 slices were analyzed, with 100µm
increment lengths between slices. To determine bone volume and polar moment of
inertia, contours were traced at the periosteal surface and calculated by Scanco IPLMoment software. To quantify the porosity of femoral cortical bone, two contours were
traced on the periosteal and endocortical surfaces of each slice and evaluated by Scanco
software. During evaluation, femur diaphysis was separated into three sections: proximal
diaphysis (2.5mm in length, slices taken from the third trochanter), mid-diaphysis (3mm
long), and distal diaphysis (2.5mm long, slices taken from the metaphysis). Porosity data
were obtained from each of these sections.
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Figure 3.2 3D microCT picture of an 8-mm long femur diaphysis

Right tibiae were fixed in 10% neural buffered formalin for 2 days, rinsed with
distilled water, and stored in 70% ethanol. Trabecular bone parameters were obtained by
microCT scan of 0.9 mm sections of trabecular bone at the proximal end of the tibia,
immediately distal to the growth plate (Figure 3.3). These parameters included trabecular
bone volume (BV), total volume (TV), percent connectivity of trabecular struts, and
trabecular volume fraction (BV/TV).
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Figure 3.3 2-D cross-sectional picture on mouse proximal tibia showing the growth plate and
trabecular bones

3.2.4 Biomechanical testing
Mechanical properties of right femora were tested following microCT analysis.
All bones were rehydrated in phosphate-buffered saline (PBS) for 1.5 hours prior to
mechanical testing to simulate in vivo properties (Broz, Simske et al. 1993). Three-point
bending tests were performed using an Instron 5582 (Merlin, Series IX software). Femora
were tested to failure with an 8 mm span length and deflection rate of 5mm/min (Figure
3.4). Force (N) and deflection (mm) were measured at the elastic limit (Pe, δe), maximum
force, and failure for all mechanically tested bones. Stiffness (S) was calculated from Pe/δ
e.
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Figure 3.4 Three point bending test on mid-femur with 8 mm span length

3.2.5 Mineral content analysis
Mineral content analysis was performed on the fractured femur. Prior to analysis,
epiphyses at both proximal and distal ends were separated. Mineral-content data were
obtained separately from epiphysis and diaphysis. Dry mass (Dry-M) was measured after
heating the bones for 24 h at 105ºC. Mineral mass (Min-M) was measured after the bones
had been ashed by baking for another 24 h at 800ºC. Percent mineralization (%Min) was
calculated by the formula % Min = Min-M/Dry-M * 100%.
3.2.6 Quantitative histomorphometry
Left femora were placed in 10% neutral-buffered formalin for 48 hours and then
stored in ethanol after being rinsed with distilled water. Bones were then allowed to airdry and embedded with noninfiltrating Epo-Kwick epoxy (Buehler, Lake Bluff, IL). The
formed disks were sectioned with a low-speed saw (Buehler, 12.7cm x 0.5mm diamond

67
blade) at the mid-diaphysis of the femur. The sections were wheel-polished to a flat,
smooth surface using 600-, 800-, and 1200-grit carbide paper followed by polishing with
a cloth impregnated with 6 µm diamond paste. This allowed micrographs at 50X
magnification to be taken of the bone cross-sections under a far blue light (400 nm).
Green calcein labels were visualized, indicating the bone formation sites during the
period of the study (Figure 3.5). Quantitative histomorphometric analysis was performed
using these photographs and SigmaScan Pro software (SPSS, San Rafael, CA).
Measurements of bone morphology (Parfitt, Drezner et al. 1987) included total
bone area (T.Ar) enclosed by periosteal perimeter and endocortical area (Ec.Ar). Cortical
area was calculated as T.Ar – Ec.Ar. A calcein label was injected at Day 2 of the study;
the area between the labels and the cortical perimeter was measured as bone formation
area (BFA), and linear content of the labeled perimeter was defined as active
mineralizing perimeter (aMPm). Bone-formation rates were calculated as BFR = BFA/8
days and mineral apposition rate as MAR = BFR/aMPm separately in the periosteal
(Ps.BFR, Ps.MAR) and endocortical (Ec.BFR, Ps.MAR) areas. Endocortical-bone
resorption perimeter (Ec.Rs.Pm) was also measured by quantifying the portion of the
nonlabeled surface with rough/ruffled border.
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Figure 3.5 2 D cross-sectional picture on mouse mid-femur showing fluorescent calcein labels
under Ultraviolet (UV) microscope

3.2.7 Statistics
Statistical comparisons were performed using repeated measures of analysis of
variance (ANOVA) with SigmaStat software. One-way ANOVAs, with a Tukey test for
follow-up comparisons, were used. A 95% level of significance (type I error) was used
for each of these tests. The correlation between serum TRAP-5b levels and bone strength
was obtained from Pearson Product Moment Correlation test with SigmaStat. Data are
presented as mean + standard error (SE).
3.3 Results
3.3.1 Weight loss and hypercalcemia
Mice treated with saline or 0.4 mg/kg RANKL maintained normal body mass and
blood calcium levels during the 10-day study. In HI group, an 11% weight loss was
observed at the day of sacrifice (p<0.001, Figure 3.6); this was accompanied by
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hypercalcemia symptoms, such as lethargy. Total serum calcium levels increased by 15.7
% in HI group (p<0.001 vs. VEH), while a 20.3% increase was observed in serum
phosphorus levels for HI group (p<0.001) compared to VEH, while those in LOW group
remained unchanged (Figure 3.7).
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Figure 3.6 Body mass in the HI group decreased by 11% at sacrifice when compared to body
mass at Day 0 (p< 0.001).
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Figure 3.7 Total serum calcium levels (A) increased by 15.7 % in HI group (p<0.001 vs. VEH).
A 20.3% increase was observed in serum phosphorus levels (B) for HI group (p<0.001) compared
to VEH, while those in LOW group remained unchanged.
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3.3.2 Bone turnover
Bone turnover rates were greatly accelerated by 10-day treatment of RANKL in
both doses. The bone formation marker serum alkaline phosphatase levels (ALP)
increased 224% and 321% in mice treated with low- and high-dose RANKL, respectively
(p<0.001) vs. VEH. The bone resorption marker serum TRAP-5b was increased by
83.8% and 49.2% (p<0.05) in LOW and HI group mice, respectively, relative to VEH
(Figure 3.8).
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Figure 3.8 RANKL increased bone turnover rates. (A) Serum TRAP-5b levels were accelerated
by 83.8% and 49.2% in low-and high-dose RANKL mice (p<0.05 vs. VEH). (B) Serum alkaline
phosphatase levels increased 3-fold in 0.4mg/kg RANKL (LOW) and 4-fold in 2.0mg/kg
RANKIL (HI) mice after 10 days of twice daily injections (p<0.001 vs. VEH). Data are presented
as the mean ± SE. * = significantly different from VEH.
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3.3.3 Cortical bone strength
Both doses of RANKL reduced femur maximum strength, fracture strength, and
stiffness. Maximum bending loads of femoral diaphyses were reduced by 25% (LOW)
and 19% (HI), while structural stiffness was decreased by 38.5% (LOW) and 37.4% (HI)
vs. VEH (p<0.001, Figure 3.9). In the HI group, serum TRAP-5b levels showed a
negative correlation with maximum strength of the femur (r= -0.74, p=0.01, Figure
3.10A), while serum ALP levels showed a positive correlation with maximum strength
(r= 0.68, p=0.02, Figure 3.10B).
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Figure 3.9 Bone maximum bending strength was significantly reduced in RANKL groups, by
19% to 25% (B), after 10 days of RANKL treatment (p<0.001). Femur stiffness (D) was
decreased by 38.5% and 37.4% in low-and high-RANKL groups (p<0.001), respectively. In both
RANKL treatment groups, there is a decreasing trend in elastic force (p=0.098, A) and fracture
force (C, p=0.014 Low, p=0.102 in high dose group) compared to VEH. Data are presented as the
mean ± SE. * = p<0.001, # = p<0.05 vs. VEH.
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Figure 3.10 Serum TRAP-5b levels (A) negatively correlated to femur maximum strength with
correlation coefficient r= -0.74 (p=0.01), while serum ALP levels (B) showed a positive
correlation with maximum strength (r= 0.68, p=0.02).

76
3.3.4 Bone mineral content
Whole femur dry mass measured from LOW and HI groups were significantly
lower than VEH (12.2% and 15.9% respectively; p<0.001). The reduction in BMC at the
epiphysis was greater than in the diaphysis. In the femoral epiphyses, reduction of dry
mass in HI group was 9.9% greater than LOW (P<0.05). The outcome observed in
mineral mass was similar. A dose-dependent decrease in femoral epiphyses was observed
in LOW and HI groups. As a result, femur total percent mineralization was decreased by
5.9% and 6.8% (p<0.05 vs. VEH), while the decrease in femur epiphyses was 8.9% and
12.5% in LOW and HI groups relative to VEH, respectively (p<0.001, Figure 3.11).
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Figure 3.11 RANKL reduced percent mineralization in mice femur. (A) No significant difference
in percent mineralization was observed at femur diaphysis. (B) Femur epiphysis %Min was
decreased by 8.9% and 12.5% in LOW and HI groups (p<0.001), respectively. Dose-dependence
manner was observed: Higher dose of RANKL induced lower %Min than lower dosage (p<0.05).
(C) Femur total %Min was decreased by 5.9% and 6.8% (p<0.05) by low and hi dose of RANKL.
Data are presented as the mean ± SE. * = significant difference compared to VEH.

3.3.5 Bone volumes indicated by MicroCT
Cortical bone parameters were measured and calculated in an 8 mm span of the
femur diaphysis. Moment of inertia at the mid-femur remained unchanged between
groups (Figure 3.12). Cortical bone volumes from LOW and HI groups were significantly
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lower than VEH (12.5% and 9.4% respectively; p<0.001, Figure 3.13A). Trabecular
parameters were measured from a 0.9 mm thick section of trabecular bone in proximal
tibia. Trabecular volume fraction (BV/TV) was decreased drastically, by 85%, in both
RANKL groups compared to VEH (p<0.001, Figure 3.13B).

pMOI at Mid-Femur
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0.05

0
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HI

Figure 3.12 No differences were observed in polar moment of inertia at femur mid-diaphysis.
Data are presented as the mean ± SE.
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Figure 3.13 RANKL reduced both cortical and trabecular bone volume. (A) Cortical bone
volume was measured and calculated in an 8-mm section of femur diaphysis. RANKL
significantly reduced cortical bone volume by 13% and 10% in low-and high-dose RANKL
groups (p<0.001 vs. VEH). (B) Trabecular bone parameters were measured from a 0.9mm section
of trabecular bone at proximal tibia. RANKL drastically reduced trabecular bone fraction
(BV/TV) in both treatment groups by 85% (p<0.001 vs. VEH). Data are presented as the mean ±
SE. * = significant difference between VEH.
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Figure 3.14 3D microCT pictures of 2-mm sections of trabecular bone at proximal tibia illustrate
severe bone loss induced by RANKL.

3.3.6 Quantitative histomorphometry
Quantitative histomorphometric analysis (Table 3.1) of the femur mid-diaphysis
revealed that endocortical bone resorption was sharply increased in both RANKL
treatment groups. Endocortical area was increased by 8.9% and 7.8% (p<0.05) in LOW
and HI groups, respectively, due to the increase in bone resorption at the endocortical
surface; this is evidenced by greater endocortical resorption perimeters of 83% and 79%
in LOW and HI groups, respectively. This increase in resorption led to a decrease of
cortical area of 6.3% and 7.8% in LOW and HI groups (p<0.05), respectively.
RANKL increased cortical bone turnover rate, as evidenced by significant
elevations of periosteal bone-formation rate with low-dose (87.3%, p<0.001) and highdose RANKL (63.9%, p<0.05) versus VEH. Increases in endocortical bone formation
rates were not observed, perhaps because bone resorption on this surface was sufficiently
robust to remove the fluorochrome label. Consistently, active mineralizing perimeters
were increased for the periosteal surface (p<0.05) but decreased at the endocortical
surface (p<0.001). Similarly, RANKL increased mineral apposition rates in both
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periosteal and endocortical surfaces, leading to an increase of 33% (p<0.001) and 23%
(p<0.05) in LOW and HI groups, respectively. Because of the increase in periosteal bone
formation and endosteal bone resorption, no significant change was observed in polar
moment of inertia of the femur diaphysis.
Table 3.1 Quantitative histomorphometry at femur mid-diaphysis: Measurements were taken
from the UV microscope photographs of the mid-diaphysis cross section. Ec = endocortical, Ps =
periosteal, Tt = total, Ar = area, B = bone, BFR = bone formation rate, aMPm = active
mineralizing perimeter, MAR = mineral apposition rate, Ec.Rs.Pm = endocortical resorption
perimeter, pMOI = polar moment of inertia at mid-diaphysis. Data are presented as mean ± SE. *:
data are significantly different vs. VEH at p<0.001. #: data are significantly different vs. VEH at
p<0.05. a: p=0.07, b: p=0.06, c: p=0.08.
Measurement

Vehicle

2

RANKL treated
0.4 mg/kg (Low)

2 mg/kg (Hi)

#

0.97 ± 0.01#

Ec.Ar. (mm )

0.90 ± 0.01

0.98 ± 0.02

Ct. Ar (mm2)

0.64 ± 0.02

0.60 ± 0.01#

0.59 ± 0.01#

Tt.B.Ar (mm2)

1.55 ± 0.02

1.57 ± 0.02

1.56 ± 0.01

0.151 ± 0.004

0.136 ± 0.002#

0.135 ± 0.002#

Ec.BFR (10-3 mm2/day)

3.76 ± 0.30

2.96 ± 0.14#

3.09 ± 0.32

-3

Ps.BFR (10 mm /day)

1.66 ± 0.18

3.11 ± 0.33*

2.72 ± 0.21#

Tt.BFR (10-3 mm2/day)

5.42 ± 0.36

6.07 ± 0.39

5.81 ± 0.41

Ec.aMPm (mm)

2.24 ± 0.15

1.44 ± 0.05*

1.56 ± 0.13*

Ps.aMPm (mm)

1.14 ± 0.05

1.39 ± 0.10#

1.37 ± 0.05 a

Tt. aMPm (mm)

3.38 ± 0.17

2.83 ± 0.12#

2.93 ± 0.10 b

Ec.MAR (10-3 mm/day)

1.68 ± 0.10

2.06 ± 0.07#

1.96 ± 0.11 c

Ps.MAR (10-3 mm/day)

1.42 ± 0.11

2.15 ± 0.17*

1.96 ± 0.11#

Tt.MAR (10-3 mm/day)

1.60 ± 0.07

2.13 ± 0.09*

1.97 ± 0.10#

Ec.Rs.Pm (mm)

1.12 ± 0.09

2.05 ± 0.09*

2.01 ± 0.12*

Ct.Th (mm)
2
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3.3.7 Femur diaphysis cortical porosity
Cortical porosity at the femur diaphysis was increased by 25.9% and 45.1% in
LOW and HI groups (p<0.001) vs. VEH.

By separating the femur diaphysis into

proximal diaphysis, mid-diaphysis, and distal diaphysis, we found that RANKL had
differential effects on these sites (Figure 3.15). Pore size and number at the trochanter
(proximal) were increased in both LOW and HI groups, resulting in 54.8% and 82%
increase of porosity (p<0.001) vs. VEH. In the distal femur, porosity was increased by
38.6% in HI group (p<0.001); the change in LOW was not significant. There was a trend
towards increased porosity at mid-diaphysis in both RANKL groups (p=0.08) compared
to VEH.
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Figure 3.15 RANKL increased cortical porosity at the femur diaphysis. By dividing the femur
diaphysis (8mm long scan area) to distal diaphysis (distal 2.5mm), mid-diaphysis (middle 3mm)
and proximal diaphysis (proximal 2.5mm), we observed different effects on different sites of
femur. (A) At distal femur, high dose RANKL caused an increase of 38.6% in porosity; the
change in the low-dose RANKL group was not significant. (B) There was a trend of increased
porosity at mid-diaphysis (p=0.08) by both doses of RANKL. (C) Both low and hi dose of
RANKL increased porosity at the proximal diaphysis (trochanter) by 54.8% and 82% in LOW
and HI groups, respectively. (D) Whole femur cortical porosity was increased by 25.9% and
45.1% in LOW and HI groups. Data are presented as mean ± SE. * = p<0.001 vs. VEH. # =
p<0.05 vs. LOW.
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Figure 3.16 2-D microCT images from 4mm to plateau (A) and 2mm to plateau (B) at proximal
tibia were taken to demonstrate cortical porosity.

Cortical porosity at the total femur diaphysis was examined for correlations. It
was observed to be associated with reduced bone strength, as shown by a negative
correlation between porosity in the HI group and the maximum strength of the femur (R=
-0.76, p=0.007, Figure 3.17).
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Figure 3.17 In the HI group, whole femur porosity negatively correlated to femur maximum
strength with correlation coefficient r= -0.76 (p= 0.007).

3.4 Discussion
High bone turnover is thought to contribute to fracture incidence in
postmenopausal osteoporosis subjects (Hochberg, Greenspan et al. 2002). One potential
etiological factor in the high turnover state of postmenopausal osteoporosis is RANKL
(Eghbali-Fatourechi, Khosla et al. 2003), a TNF family member that is essential for
osteoclast formation, function and survival (Lacey, Timms et al. 1998; Lacey, Tan et al.
2000). There are numerous animal models for studying the impact of high-turnover bone
disease on bone quality and bone strength, and ovariectomy (OVX) is the most
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commonly used. OVX recapitulates many of the important skeletal changes associated
with postmenopausal osteoporosis, including increased osteoclast and osteoblast
numbers, reduced bone volume and density, and decreased strength of trabecular sites
such as the lumbar vertebrae (Kostenuik, Capparelli et al. 2001; Kostenuik, Bolon et al.
2004). While postmenopausal osteoporosis is associated with increased fracture incidence
at both cortical and cancellous sites, OVX does not consistently result in reductions in
cortical bone strength in mice or rats. We have used soluble RANKL to develop a new
animal model of high-turnover bone disease that recapitulates many of the deleterious
skeletal changes associated with postmenopausal osteoporosis, including a reduction in
the strength of cortical bone. Advantages of this model include its rapidity (10 days) and
the lack of surgical intervention.
There are limited data on the direct catabolic effects of RANKL on bone. Shortterm (3-day) injection of RANKL resulted in reduced cancellous bone volume and
hypercalcemia (Lacey, Timms et al. 1998), but the effects of RANKL injections on bone
mineralization, formation, geometry, and strength have not been previously described. In
an isolated report, the overexpression of soluble RANKL in transgenic mice was shown
to increase bone turnover and reduce bone density and femur strength, suggesting that
continuous exposure to excess RANKL can mimic some of the cortical changes
associated with postmenopausal osteoporosis (Mizuno, Kanno et al. 2002). However, the
skeletal changes in these mice are partially related to overexpression of RANKL during
the early growth and development of the skeleton, which would limit the utility of these
mice as a model of postmenopausal osteoporosis. In contrast, the direct injection of
soluble RANKL can create osteoporosis-like changes that can be monitored over a short
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period of time in young or adult animals. An interesting observation with RANKL
transgenic mice was that the skeletal phenotype appeared to be less severe than the
phenotype associated with OPG knockout mice. This could imply that the local and
systemic absence of the endogenous RANKL inhibitor OPG results in skeletal changes
that cannot be mimicked by systemic exposure to soluble RANKL. Alternatively,
transgene expression may have been too modest in these animals to fully overcome the
local inhibitory effects of OPG. The latter possibility is supported by the current data,
wherein the direct injection of high doses of soluble RANKL created a skeletal
phenotype that was very similar to that associated with the total ablation of OPG (Bucay,
Sarosi et al. 1998; Mizuno, Amizuka et al. 1998; Min, Morony et al. 2000; Nakamura,
Udagawa et al. 2003). The phenotypic similarities included increased serum alkaline
phosphatase, decreased bone volume and density, reduced mineralization, increased
cortical porosity and reduced strength.
The ability of soluble RANKL to increase local and systemic bone resorption
parameters was shown by increases in endocortical resorption, cortical porosity, and
serum TRAP-5b (a specific marker of osteoclasts). While intracortical remodeling is not
a common finding in mice, it appears that excessive RANKL activity can lead to this
pathologic change. The strong negative correlation between cortical porosity and bone
strength suggests a possible mechanism by which excessive RANKL activity might
contribute to reduced cortical bone quality and strength.
Increased endocortical bone resorption perimeter was associated with an enlarged
medullar cavity and a decrease in cortical area and thickness. These results are consistent
with the previous finding that OPG knockout mice have increased endocortical osteoclast
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surface, which was reversed by the transgenic overexpression of soluble OPG (Min,
Morony et al. 2000). Another negative consequence of high bone turnover is an increase
in cortical porosity. Increased cortical porosity appears to account for a substantial agerelated decline in bone strength (McCalden, McGeough et al. 1993), and cortical porosity
in hip fracture cases shows a distinct regional (non-homogenous) distribution (Bell,
Loveridge et al. 1999). In our study, administration of RANKL induced cortical porosity
of the femur by increasing both the size and number of pores. Cortical porosity was
region-specific, with significant increases observed in the proximal and distal metaphyses
of the femoral diaphysis but not the mid-diaphysis. Despite the lack of porosity at the
mid-diaphysis, bone strength at this location was reduced by RANKL based on 3-point
bending tests that created mid-shaft fractures. This location was associated with increased
endocortical area and reduced cortical thickness, area and volume, which were likely
contributors to the observed reduction in bone strength. The potential contribution of
porosity to reduced bone strength at the distal and proximal femur shaft was not
determined, and would be better studied in larger species such as the rat. Compositional
analysis data of the femora revealed reduced mineralization with RANKL injections. The
dose-dependent reduction in percent mineralization was more significant in trabecular
bone than in cortical bone, suggesting changes in materials properties in addition to
structural changes described.
Previous studies have shown that markers of bone formation (e.g. serum alkaline
phosphatase) tend to increase following periods of bone resorption, due to the normal
physiological coupling between osteoblasts and osteoclasts (Bucay, Sarosi et al. 1998;
Nakamura, Udagawa et al. 2003). In this study, RANKL injections increased local and
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systemic bone formation paramaters, as indicated by a 3- to 4-fold increase in serum ALP
levels and a significant increase in periosteal bone formation rate. The increase in bone
formation is likely related to normal physiological coupling, a process that is preserved in
settings of RANKL inhibition (Nakamura, Udagawa et al. 2003). Our data suggest that
excessive RANKL also leads to a coupling-related increase in bone formation. While
positive, the compensatory effect of RANKL on periosteal bone formation was
apparently insufficient to counteract deleterious effects on endocortical area and cortical
thickness, area and volume. These cortical changes are somewhat reminiscent of changes
that were recently described in a longitudinal analysis of cortical bone geometry in
subjects with postmenopausal osteoporosis (Ahlborg, Johnell et al. 2003). Menopause
was accompanied by a progressive decrease in femur BMD and an increase in
endocortical diameter, while periosteal diameter increased over time. It was proposed that
this periosteal expansion may occur as a naturally reaction to the menopause-related
decline in BMD and increase in endocortical resorption (Ahlborg, Johnell et al. 2003). In
our study, increased periosteal bone formation may have contributed to the maintenance
of a normal polar moment of inertia at the femur diaphysis, despite the increase in
endocortical area. This constructive periosteal response may have helped to limit the loss
of cortical bone strength associated with RANKL injections, but longer-term follow up
would be required to determine if absolute periosteal expansion occurs in association
with RANKL injections and if the new bone is of a competent nature with appropriate
material properties.
This study has some limitations, including the lack of an obvious dose-response
for many of the endpoints. We believe that a lower dose range would have provided a
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clearer dose response for the majority of parameters. Dose-dependent weight loss and
hypercalcemia are consistent with the notion that the twice-daily injection of RANKL at
2 mg/kg was an excessive dose that resulted in toxicity. It remains possible that a oncedaily dose of RANKL at 0.4 mg/kg or lower could recapitulate many of the deleterious
skeletal effects we describe with twice-daily dosing, but without signs of the harmful
response. Another limitation is that we did not study changes in cancellous bone
compartments, primarily because mice have modest cancellous bone volume and the
biomechanical testing of mouse vertebrae is challenging. Rat studies would be a preferred
model for characterizing the effects of RANKL on cancellous bone, and preliminary data
have been recently described (Yuan, Kostenuik et al. 2006 (Abstract)).
3.5 Conclusions
In this study, we have demonstrated that the direct injection of soluble
recombinant RANKL levels caused severe and rapid catabolic effects on both trabecular
and cortical bone. These effects include increased bone resorption, reduction of cortical
and trabecular mineral content, reduction of cortical and trabecular bone volume, increase
in cortical bone porosity, and reduction of cortical bone strength. These data establish a
new non-surgical model for rapid bone loss in mice, which is characterized by cortical
and cancellous changes that are similar to those associated with OPG gene ablation and
more severe than those associated with ovariectomy. The ability of systemic RANKL
injections to mediate these changes suggests that soluble RANKL could be involved in
pathologic bone loss, although further studies are clearly needed to evaluate the relative
role of soluble versus membrane RANKL in the regulation of bone resorption. This
model may be relevant for bone loss initiated by local and/or systemic changes that are
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associated with osteoporosis and joint destruction associated with inflammation (Kong,
Feige et al. 1999; Eghbali-Fatourechi, Khosla et al. 2003).
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CHAPTER 4
RANKL INFUSION AS A DISEASE MODEL: INDICATIONS ON SKELETAL
DETERIORATION
Data related to this chapter has been submitted as a manuscript to Journal of Bone
and Mineral Research. Contents presented here are the manuscript formatted following
dissertation requirements.

4.1 Introduction
Bone remodeling is a continuous lifelong process that plays an important role in
regulating bone structure and function.

Bone remodeling is homeostatic when the

amount of bone resorbed during each remodeling cycle is matched by subsequent bone
formation and refilling of the remodeling site. Bone resorption exceeds bone formation
in many pathological states, leading to net bone loss, inferior bone architecture, and
increased fracture risk (Coleman 1997; Hofbauer and Schoppet 2004; Blair, Zhou et al.
2006). The bone remodeling process is regulated by a variety of hormones and cytokines
(Teitelbaum 2000; Boyle, Simonet et al. 2003), including parathyroid hormone (PTH),
interleukin-1 (IL-1), tumor necrosis factor α (TNF-α), transforming growth factor β
(TGF-β), vitamin D3, and macrophage colony stimulating factor (M-CSF) (Suda,
Takahashi et al. 1999; Teitelbaum 2000; Boyle, Simonet et al. 2003; Zaidi, Blair et al.
2003). The initiation of bone remodeling requires the presence and activity of RANKL
(Receptor Activator of Nuclear Factor κB Ligand) (Morony, Capparelli et al. 1999).
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RANKL is a member of TNF superfamily that is expressed by osteoblasts (Fuller, Wong
et al. 1998), bone marrow stromal cells (Eghbali-Fatourechi, Khosla et al. 2003), and
activated T-cells (Anderson, Maraskovsky et al. 1997). RANKL stimulates bone
resorption by binding to its receptor, RANK, on the surface of osteoclasts and their
precursors, thereby promoting osteoclast formation, function and survival (Lacey, Timms
et al. 1998; Yasuda, Shima et al. 1998). OPG is a soluble decoy receptor for RANKL,
and its binding to RANKL inhibits bone resorption and prevents bone loss by preventing
RANKL-RANK interactions (Simonet, Lacey et al. 1997; Tsuda, Goto et al. 1997).
The RANKL:OPG ratio might represent a potentially important determinant of
bone remodeling (Nagai and Sato 1999; Fazzalari, Kuliwaba et al. 2001), and an
increased RANKL:OPG ratio is evident in various bone diseases (Haynes, Crotti et al.
2001; Grimaud, Soubigou et al. 2003; Stilgren, Rettmer et al. 2004). Estrogen deficiency
in postmenopausal women is associated with enhanced RANKL expression by stromal
cells and T cells, and low bone mineral density (Eghbali-Fatourechi, Khosla et al. 2003).
In an inflammatory environment, such as in rheumatoid arthritis, cytokines released by
the immune cells increase the RANKL/OPG ratio and lead to joint destruction and bone
loss (Kong, Feige et al. 1999; Lubberts, van den Bersselaar et al. 2003; Stolina, Adamu et
al. 2005). RANKL also plays an important role in malignant diseases, such as multiple
myeloma and osteolytic bone metastases. Myeloma cells enhance RANKL release and
down-regulate OPG expression, thereby increasing bone resorption and promoting bone
loss (Giuliani, Bataille et al. 2001; Standal, Seidel et al. 2002). In osteolytic bone
metastases, such as breast and lung cancer, tumor cells directly express RANKL and/or
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indirectly increase RANKL levels through expression of PTH related peptide (PTHrP),
resulting in bone lesions (Michigami, Ihara-Watanabe et al. 2001; Mundy 2002).
There are at least 3 isoforms of RANKL, including membrane-bound and soluble
forms. The membrane-bound form is the likely candidate for mediating osteoclastogenic
responses that require cell-cell contact in certain co-culture systems (Fuller, Gallagher et
al. 1991). The soluble forms of RANKL are either directly secreted, or enzymatically
cleaved from the cell surface (Ikeda, Kasai et al. 2001; Suzuki, Ikeda et al. 2004). The
relative contribution of soluble versus membrane-bound RANKL to bone turnover is
unclear, and may differ with normal versus pathological bone remodeling. Increased
soluble RANKL was observed in the serum of animals with high-turnover bone disease
associated with inflammatory arthritis (Stolina, Adamu et al. 2005). Increased serum
RANKL was also reported in patients with high-turnover bone disease (Franchimont,
Reenaers et al. 2004; Morabito, Gaudio et al. 2004; Avbersek-Luznik, Balon et al. 2005;
Geusens, Landewe et al. 2006; Kim, Kim et al. 2006). Reports of upregulated membrane
RANKL are sporadic, perhaps due to the more cumbersome nature of such analyses
compared to ELISA-based serum assays.

In one example, postmenopausal subjects

showed higher levels of RANKL on the surface of bone marrow cells compared to
premenopausal subjects, while no menopause-related differences in soluble RANKL
were observed in peripheral blood(Eghbali-Fatourechi, Khosla et al. 2003). Circulating
levels of soluble RANKL are very low, and are frequently below the detection limits of
presently available ELISA assays (Abrahamsen, Hjelmborg et al. 2005). It remains
unclear as to whether changes in serum RANKL are reflective of changes found within
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bone, which further confounds attempts to deduce from observational studies the
potential consequences of excessive RANKL on bone.
To study the skeletal pathologies associated with increased RANKL levels, we
created an animal model using normal rats exposed to four-week continuous
administration of soluble human RANKL via osmotic pumps. We hypothesized that
excessive RANKL levels would create a spectrum of skeletal changes that are typically
associated with high-turnover bone loss conditions, including reduced bone mass, density
and strength in association with the deterioration of cancellous bone architecture and
cortical bone geometry. The RANKL/OPG system has also been implicated in vascular
disease, as evidenced by the development of arterial calcification in OPG deficient mice
(Min, Morony et al. 2000). We therefore harvested aortas at the end of the study to
evaluate mineral content as a surrogate for vascular calcification.
4.2 Materials and Methods
4.2.1 Study design
The form of human RANKL used in all studies comprised amino acids 143-317, a
region that includes the entire active ligand moiety distal to the extracellular cleavage
site, as previously described (Lacey, Timms et al. 1998). This construct, which lacks
transmembrane and intracellular domains, was expressed in Chinese hamster ovary
(CHO) cells and purified at Amgen. The purified protein had a molecular weight of 27
kD. A pilot study was performed to determine safe, effective doses for continuous
RANKL administration to rats. Twenty Sprague-Dawley (SD, Harlan, Indianapolis) rats
six months of age were assigned to five groups of four rats per group. Alzet osmotic
pumps (2ML2) implanted subcutaneously in the rats for 14 days administered RANKL at
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10, 50, 100, 200, and 400 µg/kg/day dosages. Blood was collected daily from each
specimen via the saphenous vein to examine ionized calcium levels. The two highest
doses of RANKL led to significant and dose-dependent hypercalcemia (Figure 4.1), with
the 200 µg/kg/day rats recovering weight loss relatively quickly (data not shown),
indicating that this dosage has less toxicity. We therefore selected a lower dose of 175
ug/kg/day as the highest dose to study skeletal catabolism, as well as a 5-fold lower one
(35 ug/kg/day) to examine the lowest effective dosage .

Blood Ionized Calcium Levels
10 ug/kg
50 ug/kg
100 ug/kg
200 ug/kg
400 ug/kg

Ionized Calcium (mmol/L)

1.9
1.8
1.7
1.6
1.5
1.4
1.3
1.2

0

2

4

6

8

10

12

14

Days
Figure 4.1 Five groups of SD rats (n=4) received 14 days RANKL infusion at 10, 50, 100, 200
and 400 µg/kg/day dosages in the pilot study. Blood was collected daily, and ionized-calcium
levels were examined as the efficacy indicator for RANKL administration. Rats treated with 200
and 400 µg/kg/day RANKL experienced a significant hypercalcemia, which recovered to baseline
level at the end of the study. Data are presented as the mean ± SE.
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For the main study, 36 male SD rats approximately 6 months of age were
assigned to 3 groups: VEH (Vehicle control, phosphate buffered saline, n=12), LOW
(low dose RANKL, 35 µg/kg/day, n=12) and HI (high dose RANKL, 175 µg/kg/day,
n=12). On Day 0, surgeries were performed to insert the osmotic pumps (Alzet 2ML4)
subcutaneously (dorsal region) into the rats (Figure 4.2). Treatments were delivered at a
constant rate of 2.5 µl per hour in the body environment for 28 days. Injection of 20
mg/kg calcein (i.p.) at days 2 and 26 provided fluorescent labels to monitor new bone
growth. To achieve serial serum data, blood was collected intermittently at Days 0, 3, 7,
14, and 21 from the saphenous vein and at Day 28 via cardiac puncture and
exsanguination.

Figure 4.2 Diagram of Alzet osmotic pumps for drug delivery
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At sacrifice, pumps were removed and residual drug volumes were checked to
ensure drug delivery. Hind limbs were collected and cleaned of all non-osseous tissue;
and the arterial trunks dissected. Throughout the experiment, all procedures conformed to
the guidelines of Clemson University’s Institutional Animal Care and Use Committee
(Figure 4.3).
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Figure 4.3 Flowchart illustrating the study design of the RANKL infusion study
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4.2.2 Serum bone-turnover markers
Serum was collected at the time points identified. Osteocalcin and TRAP-5b were
measured by ELISA (SBA Science/IDS Inc.) as bone formation and resorption markers,
respectively. Human RANKL levels were quantified via ELISA on Day 28, using an
ELISA kit (SBA Science/IDS Inc.).
4.2.3 Micro CT
A Scanco micro CT system (µCT20, Scanco Medical AG, Bassersdorf,
Switzerland) was used to obtain both trabecular (11 µm voxel size) and cortical
parameters (13 µm voxel size). Right tibiae were separated and fixed in 10% neural
buffered formalin for 48 hours, then stored in 70% ethanol. Trabecular bone parameters
were obtained by analyzing 1.65mm (150 slices) trabecular bone immediately distal to
the growth plate at the proximal end of the tibia. These parameters include total volume
(TV), trabecular bone volume (BV), percent connectivity of trabecular struts, and
trabecular volume fraction (BV/TV). Bone mineral density data were also obtained from
the CT scans. A phantom (Scanco) with increasing density hydroxyapatite columns was
scanned by microCT; the linear curve of hydroxyapatite content was used as the standard
curve to obtain the mineral content of the bones. Bone density data were calibrated to
milligrams of hydroxyapatite per cubic centimeter.
Left femora were air-dried and scanned for cortical parameters. A 24 mm length
of femoral diaphysis was analyzed with a total of 49 slices at 500 µm increments between
slices (13 µm voxel size with 487 µm void space between slices). Cortical volume and
polar moment of inertia (pMOI) data were obtained using IPL-Moment-of-Inertia
software (Scanco).
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4.2.4 Biomechanical testing
Mechanical properties were determined from femoral diaphyses and necks. After
the cortical bone was scanned, left femora were rehydrated in phosphate buffered saline
(PBS) for 90 min prior to testing to mimic in vivo properties (Broz, Simske et al. 1993).
Three-point bending tests were performed using an Instron 5582 (Merlin, Series IX
software); femora were tested to failure with a 24 mm span length and 5mm/min
deflection rate. The force-deflection curves were analyzed to determine the strengths and
deflections at the elastic, maximum, and failure limits. Stiffness was calculated by
dividing elastic strength by elastic deflection.
Right femora were air-dried and sectioned at the middle of the third trochanter.
The proximal portions were embedded vertically in noninfiltrating Epo-Kwick epoxy
(Buehler, Lake Bluff, IL) from the mid-trochanter to 2 mm distal to the base of the
femoral neck (Ross, Bateman et al. 2001). Disks were rehydrated in PBS for 90 minutes
prior to testing and then placed firmly in the Instron 5582. Loads were applied on the
heads of the femora with a rate of 5mm/min until failure (Figure 4.4). Strengths,
deflections, and stiffness were analyzed as previously described.
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Figure 4.4 Photograph of mechanical test on femoral neck

4.2.5 Mineral content analysis
Distal epiphyses, femoral diaphyses and femoral head were separated from the
fractured left femur. Mineral content data were obtained separately from each of these
parts. Dry mass (Dry-M) was measured after heating the bones for 24 h at 105 ºC.
Mineral mass (Min-M) was measured after the bones had been ashed by baking for
another 24h at 800 ºC. Organic mass (Org-M) was calculated as Dry-M minus Min-M.
Percent mineralization (%Min) was calculated by the formula % Min = Min-M/Dry-M *
100%.
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4.2.6 Quantitative histomorphometry
The distal portions of the right femora were placed in 10% neutral-buffered
formalin for 48 hours, rinsed with distilled water, and stored in ethanol. Bones were then
air-dried for 96 hours and embedded with noninfiltrating Epo-Kwick epoxy (Buehler).
Disks were sectioned using a low-speed saw (Buehler, 12.7cm x 0.5mm diamond blade)
at the mid-diaphysis. The distal sections were wheel-polished to a flat, smooth surface
using 600-, 800- and 1200-grit carbide paper followed by polishing with a cloth
impregnated with 6 µm diamond paste. This allowed micrographs (25X magnification) of
the bone cross-sections under a far blue light (400nm wavelength). Calcein labels in bone
fluoresce green, identifying bone formation sites during the period of the study.
Quantitative histomorphometric analyses were performed using SigmaScan Pro software
(SPSS, San Rafael, CA) on these photographs.
Measurements of bone morphology included total bone area (T.B.Ar) enclosed by
periosteal perimeter and endocortical area (Ec.Ar) (Parfitt, Drezner et al. 1987). Cortical
area was calculated as T.B.Ar – Ec.Ar. At the periosteal surface, area between labels was
measured as periosteal bone formation area (Ps.BFA); linear content of the labeled area
was defined as active mineralizing perimeter (Ps.AMPm). Periosteal bone formation rates
were calculated by dividing the 24 days between the two injected labels by periosteal
bone formation area (Ps. BFR = Ps. BFA/24) and mineral apposition rate as Ps.MAR =
Ps.BFR/Ps.AMPm. At the endosteal surface, endocortical bone resorption perimeter
(Ec.Rs.Pm) was measured by quantifying the portion of the nonlabeled surface with
rough border. Bone formation was not quantified on the endocortical surface because a

108
significant portion of the calcein labels was clearly eroded in many of the rats, making
accurate measurements not possible.
4.2.7 Vascular analysis
At sacrifice, after removal of hind limbs, the entire arterial trunk from the aortic
arch to the bifurcation of the iliac arteries was dissected manually from each rat. After
being rinsed in saline, the abdominal aorta segment (1-1.5 cm length) was processed for
calcium analysis. Tissues were lyophilized, weighed, and dry weight was recorded. Dry
samples were placed in 1 ml 6 N HCl and completely hydrolyzed in a boiling water bath
for 8 hours. Samples were evaporated under a continuous stream of nitrogen gas; residual
material was dissolved in 1 ml 0.01 N HCl. Calcium content was determined with an
atomic absorption spectrophotometer (Perkin-Elmer Model 3030, Perkin-Elmer,
Norwalk, CT). Values are expressed as µg calcium/mg dry aorta (Analysis above was
performed by Dan Simionescu and Dina Basalyga).
4.2.8 Statistics
Statistical comparisons were performed using repeated measures of analysis of
variance (ANOVA) with SigmaStat software. One-way ANOVAs, with a Tukey test for
follow-up comparisons, were used. A 95% level of significance (type I error) was used
for each of these tests. The correlation between serum TRAP-5b levels and bone strength
was obtained from Pearson Product Moment Correlation test with SigmaStat. Data are
presented as mean + standard error (SE).
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4.3 Results
4.3.1 Serum markers
Expected residue drug volume was observed in each osmotic pump, indicating the
successful delivery. Serum bone turnover marker levels were greatly enhanced in the rats
treated with high-dose RANKL. TRAP-5b levels increased steeply during the first week
of the study, peaking on day 7 with a five-fold increase (p<0.001 HI vs. VEH). TRAP-5b
levels gradually declined after day 7 and eventually returned to baseline levels at sacrifice
(Figure 4.5).

Serum TRAP-5b Levels
Serum TRAP-5b (U/L)
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VEH
LOW
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15
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5
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Day 7

Day 14

Day 21

Day 28

Figure 4.5 TRAP-5b (bone resorption marker) levels in HI increased steeply during the first
week of the study, peaking on day 7 with a five-fold increase, and gradually declined to baseline
at sacrifice. Data are presented as the mean ± SE. *: p<0.001 vs. VEH.

Similarly, serum osteocalcin levels for the HI group gradually increased and
peaked on day 14 at 82% higher (p<0.001) than VEH, then decreased over the course of
the following two weeks, ending at 40% higher than the VEH (p<0.05) at sacrifice
(Figure 4.6).
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Figure 4.6 Serum osteocalcin (bone formation marker) levels in HI gradually increased and
peaked at day 14 with an 82% higher than the VEH, then decreased and ending at 40% higher
than VEH. Data are presented as the mean ± SE. *: p<0.001 vs. VEH.

Serum levels of human RANKL were measured from samples taken at sacrifice.
Human RANKL was detectable in all animals, including vehicle controls, consistent with
modest cross-reactivity of the assay’s human polyclonal RANKL antisera with
endogenous murine RANKL. Human RANKL levels in the high dose group were 5-fold
higher than levels found in VEH controls (Figure 4.7); consistent with the notion that
drug delivery was maintained for the study duration. Neither dose of RANKL caused
significant changes in body weight throughout the study.
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Figure 4.7 huRANKL levels at sacrifice were five-fold higher in HI than in VEH. Data are
presented as the mean ± SE. *: p<0.001 vs. VEH.

4.3.2 MicroCT analysis
The low dose of RANKL was generally associated with few skeletal changes that
reached statistical significance. However, analysis of trabecular bone at the proximal
tibia revealed trends towards significant reductions in trabecular bone volume (-11%, p=
0.126) and trabecular connectivity (-17%., p = 0.054) compared to VEH. For the HI
group, RANKL treatment induced significant decreases in microCT-derived measures of
cortical and trabecular bone mass. High-dose RANKL treatment resulted in 7.6%
reduction in cortical bone volume (p<0.05, Figure 4.8) and 64% reduction in trabecular
volume fraction (BV/TV, p<0.001, Figure 4.9) compared to VEH. No differences were
observed in polar moment of inertia (pMOI) at mid-femur diaphysis (Figure 4.8).

112

A

Femur Cortical Volume

Cortical Volume (mm^3)

250

*

200

150

100

50

0

VEH

B

LOW

HI

pMOI at Mid-Diaphysis
30

pMOI (MM^4)

25

20

15

10

5

0

VEH

LOW

HI

Figure 4.8 Cortical bone properties were obtained via MicroCT analysis from the femoral
diaphyses. (A) Cortical volume reduced by 7.6% in the HI group (p<0.05 vs. VEH), no change
was observed in the LOW. (B) No significance differences were observed in Polar Moment of
Inertia (pMOI) at mid-femoral diaphyses. Data are presented as the mean ± SE. *: Significant
different vs. VEH.
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Trabecular connectivity density was affected by RANKL at a relatively higher
degree: Rats treated with high dose RANKL decreased in Conn-Dens. by 86% (p<0.001,
HI vs. VEH, Figure 4.9). Bone density values were calibrated to milligrams of
hydroxyapatite per cubic centimeter. Rats in the HI group exhibited a 1.5% decrease in
bone density compared to VEH (p=0.002, Figure 4.11).

VEH

LOW

Figure 4.9 MicroCT pictures of trabecular bone at proximal tibia.

HI
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Figure 4.10 Trabecular bone properties were obtained via MicroCT analysis from the proximal
tibias. (A) Trabecular volume fraction (BV/TV) decreased by 64% in HI (p<0.001 vs. VEH),
trend of decrease was observed in LOW (p= 0.126 vs. VEH). (B) Connectivity density (ConnDens.) decreased by 86% (p<0.001) in HI, trend of decrease by 17% was observed in LOW
(p=0.054). Data are presented as the mean ± SE. *: Significant different vs. VEH.
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Figure 4.11 Bone mineral density data obtained from the trabecular bone at proximal tibia
showed a 1.5% decrease in HI compared to VEH (p<0.05. Data are presented as the mean ± SE.
*: Significantly different vs. VEH.

4.3.3 Bone strength
Low-dose RANKL did not result in any functional changes in bone strength for
either the femoral diaphysis or neck. However, high-dose RANKL treatment caused
significant reductions in parameters of bone strength. Rats treated with 175µg/kg/day
RANKL exhibited parallel declines in mechanical properties for both femoral diaphyses
and femoral necks (Figure 4.12). For the femoral diaphyses, elastic, maximum, fracturestrength and elastic-stiffness of the rats in the HI group decreased by 18%, 21%, 22%,
and 13% (p<0.05) compared to VEH, respectively. In the femoral necks, high-dose
RANKL treatment decreased elastic and maximum strength by 20% and 17% (p<0.05)
compared to VEH. In HI group rats, elastic stiffness and fracture strength exhibited
trends of decrease by 18% (p=0.061) and 17% (p=0.11) compared to VEH, respectively
(Figure 4.12).
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Figure 4.12 In femur mechanical properties, no differences were observed in the rats treated with
low-dose RANKL. However, High-dose RANKL infusion degraded femur mechanical properties
in both diaphyses and necks with a similar manner (A-D). Decreased mechanical parameters were
observed from elastic strength (A, 18%), maximum strength (B, 21%), fracture strength (C, 22%)
and elastic stiffness (D, 13%, vs. VEH) at femoral diaphyses though three-point bending tests.
Similarly, high-dose RANKL treatment decreased elastic, maximum strength by 20% (A) and
17% (B, p<0.05) and fracture strength, elastic stiffness, by 17% (C, p=0.105) and 18% (D,
p=0.061), respectively, at the femoral neck region compared to VEH. Data are presented as the
mean ± SE. *: p<0.05 vs. VEH.
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4.3.4 Bone compositional Analysis
For the LOW group, no differences were observed for Dry-M, Min-M, Org-M, or
%Min at any testing site compare to VEH. However, rats in the HI group exhibited a
2.7% (p<0.05) lower whole-femur %Min compared to VEH, and site-specific effects in
the changes of %Min were observed: Distal epiphyses and femoral heads exhibited 8.0%
and 3.0% lower %Min, respectively (p<0.001 vs. VEH); changes in femoral diaphyses
were not significant (Table 4.1).
Table 4.1 Mineral content analysis data were collected separately from femoral diaphyses, distal
epiphyses and femoral heads. No differences in dry mass (Dry-M), mineral mass (Min-M),
organic mass (Org-M) or percent mineralization (%Min = Min-M/Dry-M) were observed in any
site of the LOW group. However, rats in HI decreased 2.7% (p<0.05) whole femur %Min and
exhibited site specific effects: Distal epiphyses and femoral heads exhibited 8.0% and 3.0% lower
%Min (p<0.001 vs. VEH), while %Min in femoral diaphyses remained unchanged. Data are
presented as the mean ± SE. a, b: p<0.05, a, c: p<0.001, #: p=0.055 vs. LOW.
Measurement

VEH

LOW
(35µg/kg RANKL)

HI
(175µg/kg RANKL)

Dry-M (mg)

664 ± 13

676 ± 13

634 ± 12#

Min-M (mg)

422 ± 9a,b

430 ± 9a

393 ± 9b

Org-M (mg)

242 ± 5

247 ± 5

242 ± 4

%Min Whole Femur

63.5 ± 0.3a

63.5 ± 0.4a

61.8 ± 0.4b

%Min Diaphysis

68.1 ± 0.5

68.7 ± 0.3

67.9 ± 0.4

%Min Distal Epiphysis

55.3 ± 0.4

a

54.1 ± 0.6

50.9 ± 0.6c

%Min Head

65.6 ± 0.3a

65.2 ± 0.3a

63.6 ± 0.3c

a

4.3.5 Quantitative Histomorphometry
There were no morphometric, formation, or resorption-related changes in the
cortical bone of LOW rats as identified by quantitative histomorphometry. For the HI
group, analysis of the femur mid-diaphysis revealed the deleterious effects of RANKL on
cortical bone structure (Table 4.2). High-dose RANKL significantly increased
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endocortical bone resorption, as evidenced by a 50% increase in endocortical resorption
perimeter (Ec.Rs.Pm) compared to VEH. This resulted in the endocortical area (Ec.Ar)
being significantly greater in the HI group than in the LOW group (p<0.05), though the
difference versus VEH did not reach statistical difference. Periosteal bone formation rate
(Ps.BFR) was accelerated by high-dose RANKL administration, with the HI group
exhibiting a 35% higher periosteal bone formation rate than the LOW (p<0.05).
Additionally, there were trends in periosteal active mineralizing perimeter (p=0.051) and
mineral apposition rate (p=0.088) with high-dose RANKL: Both increased compared to
LOW.
Table 4.2 Quantitative histomorphometric data were obtained from cross-sections of femoral
diaphyses. No differences were observed in LOW. For HI, endocortical resorption perimeter
(Ec.Rs.Pm) increased by 50% (p<0.05 vs. VEH), leading to 20% greater endocortical area
(Ec.Ar) compared to LOW (p<0.05). Periosteal bone formation rate (Ps.BFR) was accelerated by
35% (p<0.05 vs. LOW) by high-dose RANKL administration. There were trends in periosteal
active mineralizing perimeter (Ps.AMPm) and mineral apposition rate (Ps.MAR) being increased
by high-dose RANKL compared to LOW. Bone formation was not quantified on the endocortical
surface due to a significant portion of the calcein labels being eroded. Data are presented as the
mean ± SE. a, b: p<0.05, #: P=0.066 vs. LOW; *: p = 0.051 vs. LOW; §: P=0.088 vs. LOW.
Measurement
2

VEH

RANKL treated
LOW (35 µg/kg)

HI (175 µg/kg)

Ec.Ar. (mm )

4.64 ± 0.13a,b

4.28 ± 0.18a

5.13 ± 0.22b

Tt.B.Ar (mm2)

14.08 ± 0.16

13.76 ± 0.34

14.06 ± 0.25

Ct. Ar (mm2)

9.44 ± 0.13

9.48 ± 0.21

8.93 ± 0.19#

Ps.BFR (10-3 mm2/day)

10.8 ± 0.7a,b

9.5 ± 1.0a

12.8 ± 1.0b

Ps.AMPm (mm)

12.21 ± 0.41

10.80 ± 0.66

12.51 ± 0.37*

Ps.MAR (10-3 mm/day)

0.89 ± 0.04

0.86 ± 0.04

1.01 ± 0.06§

Ec.Rs.Pm (mm)

1.62 ± 0.12a

1.54 ± 0.15a

2.43 ± 0.25b
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4.3.6 Vascular calcification
Atomic absorption spectrophotometry was used to assess calcium content in
abdominal aortas, and neither dose of RANKL caused any significant changes in calcium
content (Table 4.3).
Table 4.3 No differences were observed in the calcium content levels of the abdominal aorta.
Data are presented as the mean ± SE.
Measurement

VEH

LOW (35 µg/kg RANKL)

HI (175 µg/kg RANKL)

Abdominal aorta Ca
(µg/mg dry)

0.22 ±
0.02

0.22 ± 0.03

0.23 ± 0.02

4.4 Discussion
Numerous studies have identified the critical physiological and pathological roles
of the RANK/RANKL/OPG pathway in a variety of skeletal diseases. The RANKL:OPG
ratio may be central to the regulation of bone remodeling in postmenopausal
osteoporosis, rheumatoid arthritis, bone metastases, and other skeletal disease states. It
has been shown that postmenopausal women express higher levels of RANKL in bone
marrow preosteoblasts and T and B lymphocytes than premenopausal women or
postmenopausal women receiving estrogen replacement therapy (Eghbali-Fatourechi,
Khosla et al. 2003). Interestingly, serum RANKL levels were not different among these
patient populations, which is consistent with the possibility that serum RANKL levels do
not reflect the levels found within bone. RANKL levels in serum are typically very low
and frequently below the detection limits of current assays (Abrahamsen, Hjelmborg et
al. 2005). These limitations have made it difficult to identify the effects of RANKL on
aspects of bone mass, density, microarchitecture, geometry and quality.
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We attempted to elucidate these relationships by creating a new animal model of
high-turnover bone disease that is driven by the continuous infusion of soluble
recombinant RANKL. In rats treated with high-dose RANKL, microCT scans revealed
an overall loss of bone volume in both trabecular and cortical sites, as well as the a loss
of trabecular connectivity, which are commonly seen in skeletal diseases (Coleman 1997;
Hofbauer and Schoppet 2004). Although there were no significant differences in bone
microarchitecture in the LOW group, there were trends in both trabecular volume fraction
and trabecular connectivity with no changes in other parameters. It is interesting to note
that, for this group, there were no corresponding changes in serum markers for bone
resorption or formation at any time point during the study. Furthermore, serum levels of
human RANKL were not significantly greater than the background levels found in
vehicle-treated mice. These results suggest that RANKL may be capable of causing
deleterious changes in bone mass in the absence of marked changes in circulating levels
of RANKL itself, or biochemical markers of bone turnover. This possibility is consistent
with clinical observational studies, wherein serum RANKL concentrations failed to
correlate with bone disease despite observed increases in the levels of RANKL within
bone (Stilgren, Hegedus et al. 2003; Stilgren, Rettmer et al. 2004).
Bone turnover had been identified as one of the major factors determining bone
quality and skeletal fragility (Turner 2002; Heaney 2003). OPG-deficient mice (OPG-/-)
produce a high bone-turnover osteoporotic phenotype with significant decreases in bone
mineral density and strength (Bucay, Sarosi et al. 1998). The analysis of sequential serum
markers for the current rat study demonstrated that bone turnover responded to increased
circulating RANKL levels with a coupled increase in both bone formation and resorption.
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RANKL injections led to a maximal 5-fold increase in serum TRAP-5b, which exceeded
the maximal increase in serum osteocalcin (~2-fold). These changes, in addition to the
clear loss of bone mass, density and strength, indicate that the catabolic actions of
RANKL are not effectively countered by the observed increases in bone formation.
These effects were observed in growing gonad-intact rats, which would otherwise exhibit
a positive bone remodeling balance. These observations indicate that RANKL-mediated
bone remodeling might result in bone loss independent of age, sex hormone levels, age,
or baseline levels of bone turnover or density.
The accelerated bone resorption resulted in hypercalcemia as described in the
pilot study, which is a common metabolic complication of malignant diseases associated
with morbidity (Coleman 1997). Due to the coupling effect between osteoclasts and
osteoblasts, bone formation markers increased accordingly with a delay relative to the
increase in resorption, peaking on Day 14, and remained at high levels through the end of
the study. This sequential stimulation of bone resorption and formation correlates with
the activation sequence in normal skeleton remodeling cycle. Most osteolytic metastases
demonstrate similar changes in bone resorption and formation, with the dominant lesion
being lytic and destructive but coupled by elevated formation (Mundy 2002).
In this study, we observed that serum TRAP-5b levels returned to baseline after
28 days of RANKL infusion. To test whether this decline was related to premature
exhaustion of the osmotic pumps, we measured human RANKL levels from serum
collected at sacrifice. Significant levels of human RANKL were observed at the end of
the study in the high-dose group, which indicates that drug delivery was maintained
throughout the study. However, RANKL concentrations were relatively low at the end of
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the study (~250 pg/ml in the high-dose group) and it is possible that immune responses
against human RANKL led to lower drug exposure during the latter phase of the infusion
period. Nonetheless, the high-dose infusion regimen was shown to cause significant bone
loss over a 4 week period, which establishes this as a useful model of high-turnover bone
disease for future studies. It is also possible that the gradual recovery of serum TRAP-5b
levels during the latter phase of RANKL infusion was related to a homeostatic response
that attempts to minimize the severity of bone loss. The osteoporotic phenotype of OPGdeficient mice shows that even a lifetime of unopposed RANKL activity does not lead to
complete resorption of the skeleton (Bucay, Sarosi et al. 1998). It is therefore likely that
compensatory mechanisms eventually defend the skeleton against the extremes of bone
loss, perhaps via a feedback increase in bone formation.
A direct consequence of this high bone turnover model was degraded bone
quality, which includes poor material properties and inferior bone architecture. Bone
mineralization status can be indicated as material properties. When calibrated with
hydroxyapatite content, bone density on trabecular bone showed a 1.5 % decrease in the
HI compared to VEH as revealed by MicroCT . The changes in mineralization status
were also indicated by the decrease of percent mineralization at bone cortical and
trabecular regions. Both techniques demonstrate that high-dose RANKL infusion resulted
in poor mineralization, which is probably a consequence of the increased turnover.
Quantitative histomorphometric analysis of the femoral mid-diaphyses revealed
the effects of RANKL on cortical bone. The decreased femoral cortical volume, as
identified by microCT, was caused by stimulation of endocortical bone resorption, which
resulted in thinning of the cortex. This observation correlates with a previous study

123
demonstrating that OPG reverses osteoporosis by inhibiting activation of endosteal
osteoclasts (Min, Morony et al. 2000). Correlated to the high osteocalcin levels observed
in serum, periosteal bone formation rate increased in the HI group. However, this positive
effect on bone strength was counteracted by greater endocortical resorption, as confirmed
by the three-point bending test.
Strength of the femoral neck is a composite of both cortical and trabecular bone
properties. Extrapolating the cortical and trabecular changes observed at other sites, it is
clear that the combination of reduced trabecular architecture, poor trabecular
mineralization, and inferior cortical structure resulting from high-dose RANKL infusion
compromised strength at the femoral neck. These observations in gonad-intact rats are
consistent with data showing that the ratio of RANKL:OPG is elevated in
postmenopausal women with prevalent hip fractures (Abdallah, Stilgren et al. 2005). The
ability of RANKL inhibitor to improve femoral neck BMD and geometry in
postmenopausal women appears to confirm that RANKL plays a role in bone turnover at
this clinically important skeletal site (Beck, Miller et al. 2006).
Vascular

calcification

has

been

indicated

to

be

closely

related

to

RANK/RANKL/OPG pathway; OPG knock-out mice develop arterial calcification of the
renal arteries and aorta (Min, Morony et al. 2000). However, analysis of the calcium
content from abdominal aortas indicated that continuous RANKL administration did not
cause vascular calcification. It is possible that systemic exposure to RANKL does not
induce or exacerbate vascular disease. Alternatively, RANKL-related changes in the
vasculature might require a longer infusion period or the presence of additional vascular
insults or challenges.

This study utilized healthy rats, and it remains possible that
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RANKL could have deleterious effects on the vasculature in animals that are more
susceptible to vascular disease.
4.5 Conclusions
In summary, high-dose RANKL infusion resulted in systemic bone loss and
decline in bone quality and structural integrity that were comparable to the skeletal
complications caused by diseases such as osteoporosis. Thus, therapies targeting
inhibition of RANKL may be a viable approach in treating skeletal complications of
these bone diseases (Body, Facon et al. 2006; McClung, Lewiecki et al. 2006).
Continuous administration of RANKL resulted in low bone mass and reduced bone
strength without obvious complications or toxicities. Modification of RANKL
administration (local to a joint rather than systemic) could possibly mimic the periarticular bone loss and/or focal bone erosions that are associated with rheumatoid
arthritis. The model presented here (and variations thereof) could have utility as a model
of high-turnover bone disease, and for characterizing the potential role of the
RANKL/RANK/OPG pathway for multiple skeletal diseases.
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CHAPTER 5
CHARACTERIZATION OF M-CSF AS AN ANABOLIC AGENT FOR BONE
BIOMECHANICS
5.1 Introduction
Macrophage colony-stimulating factor (M-CSF, also named CSF-1) was defined
originally by its ability to stimulate the growth and development of macrophage colonies
from bone marrow precursors (Stanley, Guilbert et al. 1983). Subsequent studies showed
that M-CSF is a haematopoietic growth factor that stimulates the proliferation,
differentiation, and survival of cells from the mononuclear phagocytes lineage, including
macrophages and osteoclasts (Hume, Pavli et al. 1988; Rettenmier and Sherr 1989;
Hattersley, Owens et al. 1991). M-CSF is produced primarily by connective tissue cells,
including stromal cells and osteoblasts. Through alternative mRNA splicing of a unique
gene, these cells synthesize three mature isoforms of M-CSF, including a membranebound glycoprotein, an extracellular matrix-anchored proteoglycan, and a soluble
glycoprotein that is rapidly secreted into the circulation (Stanley, Berg et al. 1994). These
M-CSF isoforms act on target cells through a specific cell-surface tyrosine kinase
receptor (CSF-1R) that is encoded by the c-fms proto-oncogene (Pixley and Stanley
2004).
In bone, M-CSF acts as a key regulator of osteoclastogenesis both in vitro and in
vivo. Previous studies showed that M-CSF is necessary for both proliferation and
differentiation of osteoclast progenitors as well as for their survival (Fuller, Owens et al.
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1993; Tanaka, Takahashi et al. 1993). In a coculture system of mouse osteoblasts and
spleen cells, osteoclast formation induced by 1,25(OH)2 Vitamin D3 was inhibited when
the coculture system was incubated with either anti-M-CSF or anti-M-CSF receptor
antibodies during the proliferation or differentiation phase (Tanaka, Takahashi et al.
1993). The role of M-CSF in osteoclastogenesis in vivo has been confirmed using MCSF-deficient osteopetrotic (op/op) mouse model. Transgenic mice with specific knockout of the M-CSF gene developed profound osteopetrotic phenotypes with little or no
osteoclast activity (Wiktor-Jedrzejczak, Bartocci et al. 1990; Yoshida, Hayashi et al.
1990). Subsequent studies demonstrated that systemic administration of recombinant
human M-CSF to op/op mice increased the number of osteoclasts and led to partial or
complete resolution of the osteopetrotic defect (Kodama, Yamasaki et al. 1991; Abboud,
Woodruff et al. 2002).
It is clear that M-CSF stimulates osteoclastogenesis by promoting early entry of
progenitors into the osteoclast lineage. However, there is no evidence that M-CSF
stimulates the later stages of osteoclastogenesis, such as fusion and activation, or
subsequent bone resorption (Biskobing, Fan et al. 1995; Udagawa, Takahashi et al.
1999). In fact, several studies have reported that high concentrations of M-CSF can
suppress osteoclast formation and activation in vitro (Hattersley, Dorey et al. 1988;
Fuller, Owens et al. 1993; Perkins and Kling 1995). For example, Perkins et al. showed
that exogenous M-CSF caused a dose-dependent 98% decrease in tartrate-resistant acid
phosphatase (TRAP)-positive multinucleated cells in a coculture system of ST-2 stromal
cells and murine bone marrow cells (Perkins and Kling 1995). In studies using isolated
mature rat osteoclasts, Hattersley and Fuller demonstrated that M-CSF inhibited bone
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resorption by reducing the proportion of osteoclasts that were resorbing bone (Hattersley,
Dorey et al. 1988; Fuller, Owens et al. 1993). Furthermore, addition of M-CSF has been
shown to down-regulate the expression of its receptor c-fms on macrophages and isolated
osteoclasts (Panterne, Zhou et al. 1993; Amano, Hofstetter et al. 1995; Fan, Biskobing et
al. 1997).
These findings suggest a complex action of M-CSF in bone physiology: It
stimulates the proliferation and differentiation of osteoclast progenitors but exhibits
antiresorptive effects by inhibiting formation of mature osteoclasts and their functional
activities. Recently, studies showed that mice over-expressing M-CSF or receiving daily
M-CSF injections increased cortical bone formation and improved cortical bone material
and biomechanical properties (Hermann 2000; Abboud, Ghosh-Choudhury et al. 2003).
Osteoblasts play an integral role in regulating osteoclastogenesis through both
cell-cell interactions and release of cytokines (Takahashi, Akatsu et al. 1988; Teitelbaum
2000). These bone formation responses, possibly induced by the coupling phenomena
between osteoclasts and osteoblasts (Nishino, Amizuka et al. 2001), demonstrate the
potential of M-CSF as an anabolic agent for osteolytic bone diseases, such as
osteoporosis. However, many important anabolic indicators of the skeleton, such as bone
turnover rates and trabecular bone formation and geometry, have not been examined. In
the present study, we explored a series of functional changes of the skeleton in response
to different doses of M-CSF, with the aim of further characterizing its potential as an
anabolic agent.

133
5.2 Materials and Methods
5.2.1 Study design
Prior to the main study, two pilot studies were performed using lower doses of MCSF. In study I, seven-week-old C57BL/6J male mice (Jackson Laboratory, Bar Harbor,
ME) received two different doses of M-CSF (0.01 mg/kg/day, 0.1 mg/kg/day) via daily
injections for 3 weeks. In study II, mice of the same strain and age received a 4-week
administration of two higher doses of M-CSF (0.5 mg/kg/day, 1 mg/kg/day) via both
daily injections and continuous administrations using osmotic pumps. At sacrifice, hind
limbs were removed and analyzed; no differences in bone volume, geometry,
mineralization, or strength were observed. Therefore, a higher dose of M-CSF
(5mg/kg/day) was selected in this study to examine its in vivo effects on bone
biomechanics.
In the main study, twenty-four male C57BL/6J mice aged 7 weeks were assigned
to one of two groups, VEH (placebo control, phosphate buffered saline, n=12) or M-CSF
(5 mg/kg/day, n=12). The protein used in this project was donated by Chiron
(Emeryville, CA); it was an unglycosylated 49-kDa homodimer (a truncated form of
native M-CSF) that was expressed in Escherichia coli and stored as a lyophilized powder.
All mice received daily subcutaneous injections (0.2 ml per injection) for 21 days. Body
weights were monitored every three days, and drug concentrations were adjusted
accordingly. Calcein (20 mg/kg) was injected (i.p.) as a fluorescent label at Day 2 to
monitor new bone growth. On Day 21, animals were anesthetized with isoflurane and
euthanized by exsanguination followed by cervical dislocation. Both hind limbs were
removed and cleaned of all nonosseous tissue; spleens were also collected and weighted.
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All procedures performed throughout the experiment conformed to the guidelines of
Clemson University’s Institutional Animal Care and Use Committee (Figure 5.1).
5.2.2 Serum bone-turnover markers
Serum was obtained at sacrifice, and markers for bone formation and resorption
were measured. Serum osteocalcin and TRAP-5b levels were measured as markers of
bone formation and bone resorption by ELISA (SBA Science/IDS Inc.), respectively.
5.2.3 Micro CT
Left tibiae and femurs were fixed in 10% neural buffered formalin for 2 days,
rinsed with distilled water, and stored in 70% ethanol. Cortical and trabecular parameters
were obtained from the microcomputed tomography analysis (µCT20, Scanco Medical
AG, Bassersdorf, Switzerland) with a voxel size of 9 µm in all three spatial dimensions
(Ruegsegger, Koller et al. 1996; Dufresne 1998). Left femoral diaphyses were scanned,
and a total of 75 slices, with 100µm increments between slices, were analyzed for cortical
bone parameters. To determine bone volume and polar moment of inertia, contours were
traced at the periosteal surface and calculated by Scanco IPL-Moment software.
Trabecular bone parameters were obtained from the microCT scans of 0.9 mm
trabecular bone sections at the proximal end of tibiae, immediately distal to the growth
plate. These parameters included trabecular bone volume (BV), total volume (TV),
connectivity density (Conn. Dens.) of trabecular struts, trabecular number (Tb.N), and
trabecular separation (Tb.Sp). BV was normalized with TV to obtain trabecular volume
fraction (BV/TV). Trabecular number was calculated by taking the inverse of the mean
distance between the middle axes of the trabeculae; trabecular separation was calculated
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by measuring 3D distances directly in the trabecular network and taking the mean over all
voxels. A phantom (Scanco) with increasing density hydroxyapatite columns was
scanned by microCT; the linear curve of hydroxyapatite content was used as the standard
curve to obtain the mineral content of the bones. Bone density data were obtained and
calibrated to milligrams of hydroxyapatite per cubic centimeter.
5.2.4 Biomechanical testing
Mechanical properties of left femora were tested following microCT analysis. All
bones were removed from ethanol, rinsed with distilled water, and rehydrated in
phosphate-buffered saline (PBS) for 1.5 hours prior to mechanical testing. Three-point
bending tests were performed using an Instron 5582 (Merlin, Series IX software). Femora
were tested to failure with an 8 mm span length and deflection rate of 5mm/min. Force
(N) and deflection (mm) were measured at the elastic limit (Pe, δe), maximum force, and
failure for all mechanically tested bones. Stiffness (S) was calculated from Pe/δe.
5.2.5 Mineral content analysis
Mineral content analysis was performed on the fractured femur. Prior to analysis,
epiphyses at both proximal and distal ends were separated. Mineral-content data were
obtained separately from epiphyses and diaphysis. Dry mass (Dry-M) was measured after
heating the bones for 24 h at 105ºC. Mineral mass (Min-M) was measured after the bones
had been ashed by baking for another 24 h at 800ºC. Percent mineralization (%Min) was
calculated by the formula % Min = Min-M/Dry-M * 100%.
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5.2.6 Quantitative histomorphometry
Left femora were air-dried and embedded with noninfiltrating Epo-Kwick epoxy
(Buehler, Lake Bluff, IL). The formed disks were sectioned with a low-speed saw
(Buehler, 12.7cm x 0.5mm diamond blade) at the mid-diaphysis of the femur. The
sections were wheel-polished to a flat, smooth surface using 600-, 800-, and 1200-grit
carbide paper followed by polishing with a cloth impregnated with 6 µm diamond paste.
This allowed micrographs at 50X magnification to be taken of the bone cross-sections
under a far blue light (400 nm). Green calcein labels were visualized, indicating the bone
formation sites during the period of the study. Quantitative histomorphometric analysis
was performed using these photographs and SigmaScan Pro software (SPSS, San Rafael,
CA).
Measurements of bone morphology (Parfitt, Drezner et al. 1987) included total
bone area (Tt.B.Ar) and endocortical area (Ec.Ar), cortical area was calculated as Tt.B.Ar
– Ec.Ar. Bone formation area (BFA) was obtained by measuring the area between the
labels and the cortical perimeter, and linear content of the labeled perimeter was defined
as active mineralizing perimeter (aMPm). Bone-formation rates were calculated as BFR =
BFA/19 days, and mineral apposition rate was calculated as MAR = BFR/aMPm
separately in the periosteal (Ps.BFR, Ps.MAR) and endocortical (Ec.BFR, Ps.MAR)
areas.
5.2.7 Statistics
Statistical comparisons were performed using unpaired t-tests with SigmaStat
software. A 95% level of significance (type I error) was used for each of these tests. Data
are presented as mean + standard error (SE).

138
5.3 Results
5.3.1 Body and spleen mass
Animal mass in both groups increased during the 21-day study. Mice in the VEH
group increased body mass from 19.5 grams at Day 0 to 21.5 grams at Day 21, while
those treated with M-CSF experienced a 55% higher net body mass gain than the VEH
mice (p=0.001); average body mass increased from 19.3 grams at Day 0 to 22.4 grams at
sacrifice. Significant differences in the net increases of body mass between VEH and MCSF groups were observed from Day 3 (p<0.001) and continued to the end of the study
(Figure 5.2). At sacrifice, spleens were removed and weighed; mice treated with M-CSF
increased in spleen mass by 80% compared to the VEH group (p<0.001).
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Figure 5.2 Animal mass in both groups increased during the 21-day study. Mice in the VEH
group increased body mass from 19.5 grams at Day 0 to 21.5 grams at Day 21. Significant
difference in net increases of body mass between VEH and M-CSF groups were observed from
Day 3 (p<0.001) and remained to the end of the study. At sacrifice, mice treated with M-CSF
gained an average of 3.1 gram body mass, increased from 19.3 grams at Day 0 to 22.4 grams,
which was 55% higher than those in the VEH mice (p=0.001). Data are presented as the mean ±
SE. * = significantly different from VEH.

5.3.2 Bone turnover
Daily administration of M-CSF stimulated general bone turnover in mice, as
evidenced by significantly increased bone formation and resorption rates. Serum
osteocalcin levels (marker of bone formation) in M-CSF group increased 44% compared
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to VEH (p<0.001). Meanwhile, the bone specific resorption marker, serum TRAP-5b
levels, increased by 57% relative to VEH (p<0.001, Figure 5.3).
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Figure 5.3 M-CSF increased both bone formation and resorption rates. (A) Serum osteocalcin
exhibited 44% higher in the M-CSF group (167ng/ml) than VEH (116ng/ml, p<0.001). (B) Serum
TRAP-5b levels in the M-CSF group (13.2 U/L) increased by 57% compared to VEH (8.4U/L,
p<0.001). Data are presented as the mean ± SE. * = significantly different from VEH.
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5.3.3 Cortical Strength
Mechanical properties of the cortical bone were obtained from femur diaphyses.
Between the groups of M-CSF and VEH, significant differences were not observed in any
of the elastic, maximum, fracture strength or energy (Table 5.1).
Table 5.1 Three point bending tests were performed on femur diaphyses to obtain mechanical
properties data of the cortical bone. Significant differences were not observed in any of the
elastic, maximum, fracture strength or stiffness. Data are presented as the mean ± SE.
Measurements

VEH

M-CSF

Stiffness (N/mm)

39.2 ± 2.1

41.5 ± 4.5

Elastic force (N)

9.05 ± 0.31

8.89 ± 0.21

Maximum force (N)

11.8 ± 0.4

11.7 ± 0.3

Fracture force (N)

6.17 ± 0.30

6.62 ± 0.38

5.3.4 Bone mineral content
Bone mineral data were obtained separately from femoral diaphyses and
epiphyses. No differences in dry mass (Dry-M), mineral mass (Min-M), organic mass
(Org-M) were observed in the M-CSF group compared to VEH. Data in percent
mineralization in sites of diaphyses, epiphyses or whole femur between groups were
similar and not significant different (Table 5.2).
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Table 5.2 Mineral content analysis data were collected separately from femoral
diaphyses and epiphyses. In the M-CSF group, no differences in dry mass (Dry-M),
mineral mass (Min-M), organic mass (Org-M) were observed compared to VEH.
Differences in percent mineralization (%Min = Min-M/Dry-M) in sites of diaphyses,
epiphyses or whole femur were also not observed (vs. VEH). Data are presented as the
mean ± SE.
Measurement

VEH

M-CSF

Dry-M (mg)

33.0 ± 0.6

32.3 ± 0.9

Min-M (mg)

20.0 ± 0.4

19.7 ± 0.5

Org-M (mg)

13.0 ± 0.2

12.7 ± 0.4

%Min Whole Femur

60.6 ± 0.1

60.8 ± 0.2

%Min Diaphysis

62.6 ± 0.3

62.6 ± 0.3

%Min Epiphysis

59.1 ± 0.3

59.1 ± 0.3

5.3.5 Bone volumes indicated by MicroCT
M-CSF caused differential effects in mouse cortical and trabecular bone. Cortical
bone volumes were measured and calculated in a 7.4 mm span of the femur diaphysis. MCSF caused a trend of decrease in cortical volume by 2.9% compared to VEH (p=0.095,
Figure 5.4A), though data did not reach statistical difference. Similar trends were
observed in the average polar moment of inertia (pMOI) data; M-CSF treatment resulted
in a trend of decrease by 5.8% in pMOI value of the femur diaphysis (p=0.074 vs. VEH,
Figure 5.4B).
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Figure 5.4 No significant differences were observed in cortical bone parameters between M-CSF
and VEH groups. However, trends of decreased cortical volume (A) by 2.9% (p=0.095) and mean
polar moment of inertia (pMOI) of femur diaphyses (B) by 5.8% were observed in the M-CSF
group compared to VEH. Data are presented as the mean ± SE. * = significantly different from
VEH.
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Trabecular parameters were measured from a 0.9 mm thick section of trabecular
bone in proximal tibia. In contrast, average trabecular volume fraction (BV/TV)
increased by 35% in the mice treated with M-CSF (p<0.001 vs. VEH, Figure 5.5A). MCSF significantly increased trabecular connectivity by 79% (p<0.001, Figure 5.5B)
compared to the VEH group.
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Figure 5.5 M-CSF stimulated trabecular bone formation. (A) Average trabecular volume fraction
(BV/TV) increased by 35% (p<0.001 vs. VEH) in mice treated with M-CSF. (B) M-CSF
significantly increased trabecular connectivity by 79% (p<0.001) compared to the VEH group.
Data are presented as the mean ± SE. * = significantly different from VEH.
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Figure 5.6 Trabecular parameters were measured with microCT from a 0.9 mm thick trabecular
bone section at proximal tibia. 3-D trabecular pictures showed the mouse treated with M-CSF has
a thicker and denser trabecular bone than that in VEH. Both pictures were obtained from mice
with median bone volume of individual groups.
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Significant differences were also observed in other trabecular parameters: M-CSF
increased trabecular number by 17.7% (p<0.001, Figure 5.7A), and lower trabecular
spacing by 17.8% (p<0.001, Figure 5.7B) compared to VEH. Bone density values were
calibrated to milligrams of hydroxyapatite per cubic centimeter. Mice in the M-CSF
group exhibited a 3.5% lower bone density than VEH (p=0.007, Figure 5.8).
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Figure 5.7 M-CSF also affected other trabecular bone parameter, such as increased trabecular
number (A) by 17.7% (p<0.001), and lower trabecular separation (B) by 17.8% (p<0.001 vs.
VEH). Data are presented as the mean ± SE. * = significantly different from VEH.
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Figure 5.8 The newly formed trabecular bone induced by M-CSF administration exhibited a
3.5% lower bone density than those in VEH (p=0.007). Data are presented as the mean ± SE. *
= significantly different from VEH.

5.3.6 Quantitative histomorphometry
As indicated by quantitative histomorphometry, M-CSF administration did not
cause significant changes in cortical geometry (Table 5.3). However, trends of increase in
periosteal mineral apposition rate (Ps.MAR, p=0.12) and total mineral apposition rate
(Tt.MAR, p=0.14) were observed in the M-CSF group when compared to VEH.
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Table 5.3 Quantitative histomorphometry measurements were taken from the UV microscope
photographs of the femur mid-diaphysis cross-sections. Ec = endocortical, Ps = periosteal, Tt =
total, Ar = area, B = bone, BFR = bone formation rate, AMPm = active mineralizing perimeter,
MAR = mineral apposition rate. Data are presented as mean ± SE.

Measurement

VEH

M-CSF

Ec.Ar. (mm2)

0.85 ± 0.03

0.82 ± 0.03

Ct. Ar (mm2)

0.81 ± 0.02

0.80 ± 0.02

Tt.B.Ar (mm2)

1.66 ± 0.03

1.63 ± 0.01

-3

2

Ec.BFR (10 mm /day)

2.11 ± 0.36

2.03 ± 0.21

-3

2

Ps.BFR (10 mm /day)

5.60 ± 0.34

6.44 ± 0.54

Tt.BFR (10-3 mm2/day)

5.42 ± 0.36

5.42 ± 0.36

Ec.AMPm (mm)

1.87 ± 0.17

1.80 ± 0.13

Ps.AMPm (mm)

3.39 ± 0.29

3.37 ± 0.30

Tt. AMPm (mm)

5.26 ± 0.31

5.17 ± 0.31

Ec.MAR (10-3 mm/day)

1.09 ± 0.12

1.12 ± 0.07

Ps.MAR (10 mm/day)

1.72 ± 0.11

1.96 ± 0.10 p=0.12

Tt.MAR (10-3 mm/day)

1.49 ± 0.07

1.65 ± 0.07 p=0.14

-3

5.4 Discussion
Bone remodeling, a lifetime process that includes bones being continuously
broken down (bone resorption) and reformed (bone formation), allows the maintenance
of bone mass and quality. Activities of osteoblasts and osteoclasts are tightly linked and
balanced under normal conditions, a phenomenon often referred to as coupling (Howard,
Bottemiller et al. 1981; Martin 1993). In this study, we observed an increase of
osteoclastogenesis, as evidenced by the 57% increase in serum TRAP-5b levels.
Meanwhile, bone formation activities (serum osteocalcin) also increased, indicating M-
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CSF indirectly stimulated bone formation through coupling of osteoblasts and
osteoclasts. The mechanism of the coupling phenomena, though not fully understood, is
generally considered to be the result of direct communication between osteoclasts and
osteoblasts by cell-cell interaction and by cytokines released to the bone
microenvironment during bone resorption (Howard, Bottemiller et al. 1981; Centrella,
McCarthy et al. 1991; Rodan 1991; Martin 1993). Previous studies have indicated that
these coupling factors might include insulin-like growth fact-1 (IGF-1), transforming
growth factor-β (TGF-β), and bone morphogenetic factor (BMP) (Centrella, McCarthy et
al. 1991; Rodan 1991; Martin 1993).
Although both bone turnover rates increased, the most evident changes in bone
came from the markedly increased trabecular volume, indicating that M-CSF dissociated
bone remodeling and functioned as an anabolic agent. Mice treated with high doses of MCSF showed increased trabecular volume (35%), connectivity density (79%), and
trabecular number (17.7%) and reduced separation (-17.8%). The newly formed
trabecular bone was less mineralized due to the high bone turnover rates, as revealed by
the microCT data. Anabolic effects of M-CSF also came from the increased body mass
observed in this study; mice treated with M-CSF gained significantly higher body weight
from Day 3 and remained throughout the whole course of this study.
Anabolic effects of M-CSF were not reflected in cortical bone. Data obtained in
this study showed that M-CSF induced a nonsignificant trend of decreasing cortical
volume and polar moment of inertia. However, these probably catabolic effects on
cortical bone did not cause significant changes in bone strength. In fact, the presence of
both anabolism and catabolism is common in most bone anabolic agents (Lacey, Timms
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et al. 1998; Poole and Reeve 2005). Other cortical bone parameters, including geometry
and mineralization, remained unchanged. Interestingly, these observations on cortical
bone are opposite compared to previous findings of increased cortical thickness or
improved mineral and mechanical properties in studies with either transgenic models or
lower-dose M-CSF administrations (Hermann 2000; Abboud, Ghosh-Choudhury et al.
2003).
The clear increases in trabecular bone parameters and the trend of decrease in
cortical bone volume indicated that M-CSF exhibits both anabolic and catabolic effects
with site-specific differences. Similar results are known in anabolic agents for
osteoporosis, such as PTH (Poole and Reeve 2005). Anabolic effects of intermittent PTH
injections were observed primarily in trabecular bone through increasing trabecular bone
volume, connectivity density and trabecular number and decreasing separation (Jiang,
Zhao et al. 2003). Along with these strong anabolic actions on trabecular bone, PTH
stimulates endocortical bone remodeling and increases cortical porosity, a catabolic effect
that has led to concern that the increases in trabecular bone parameters may be obtained
at the expense of cortical bone (Horwitz, Stewart et al. 2000; Neer, Arnaud et al. 2001;
Rubin, Cosman et al. 2002). Such site-specific anabolic and catabolic changes in bones
are similar to those induced by M-CSF in this study.
However, PTH acts anabolically by directly stimulating bone formation through
promoting differentiation of committed osteoblast precursors and inhibiting apoptosis of
osteoblasts (Dobnig and Turner 1995; Jilka, Weinstein et al. 1999) In contrast, M-CSF
targets osteoclast lineage and stimulates the proliferation and early differentiation of
osteoclast progenitors but not mature osteoclasts (Tanaka, Takahashi et al. 1993), thus
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indirectly promoting osteoblast formation via coupling. These two seemingly radically
different mechanisms may not be fully independent. Recent studies have indicated that
the resorptive action of PTH might be necessary for its anabolic effect. In a study using
ovariectomized rats treated with PTH, bone formation was partially inhibited with a
combined treatment of antiresorptive therapies (Wronski, Yen et al. 1993). Transgenic
mice with c-fos gene knock-out exhibit osteopetrotic symptoms due to defects on
osteoclast development and fail to show an anabolic response to PTH (Demiralp, Chen et
al. 2002).
In vivo studies targeting the effects of M-CSF on the skeleton system are sparse;
however, complicated action of M-CSF has been seen. In vitro studies demonstrated
divergent effects of M-CSF on osteoclast formation and bone resorption in varying
concentrations (Perkins and Kling 1995). The importance of protein concentrations was
also reflected in the pilot studies for this project. In these in vivo studies, we examined a
series of lower doses of M-CSF (0.01mg, 0.1mg., 0.5mg, and 1mg per kilogram body
mass per day) given to mice of the same strain and age as the current 5mg/kg/day M-CSF
study, and neither anabolic nor catabolic effects on the skeleton were observed in the
mice receiving lower doses. This might indicate that M-CSF causes dose-dependent bone
functional changes. In addition, administration routes and periods might also cause
different bone reactions. An in vivo study using transgenic mice that overexpressed
soluble M-CSF showed no changes in bone parameters at 5 weeks but had increased
cortical bone thickness at 14 weeks (Abboud, Ghosh-Choudhury et al. 2003). One
possible explanation for this observation might be the variety of the M-CSF-receptor
expression. Earlier studies by other groups showed that M-CSF receptors could be
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expressed at variable levels under different populations of monocyte cells and local
cytokine environments (Kreipe, Radzun et al. 1988; Gusella, Ayroldi et al. 1990). As a
stimulator of circulating monocytes and macrophages, M-CSF can influence the local
environments of its receptor. In addition, M-CSF itself can down-regulate its receptor
expression in macrophages and isolated osteoclasts (Amano, Hofstetter et al. 1995).
5.5 Conclusions
In summary, this study demonstrates the anabolic actions of M-CSF on trabecular
bone formation. These anabolic effects, probably through coupling between osteoclasts
and osteoblasts, suggest the potential of M-CSF as an anabolic agent to stimulate new
bone formation and improve bone strength. In vitro studies have shown that M-CSF in
higher concentrations exhibits unique antiresorptive effects on bone resorption; however,
these antiresorptive effects were not observed in this in vivo study. Future studies
examining changes in skeleton exposed to different dosages, administration routes, and
periods or effects in larger and skeletally mature animals like rats will be necessary to
elucidate the mechanism and utilize its anabolic potential. In addition, since soluble MCSF exhibits a relatively short clearance time in the circulation (Bauer, Gibbons et al.
1994), further modifications on molecular structures or drug delivery methods aiming to
improve the pharmacokinetics and pharmacodynamics of this protein would be valuable
in developing its unique potential as an anabolic and antiresorptive therapy for
osteoporosis.
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CHAPTER 6
CONCLUSIONS AND RECOMMENDATIONS
This dissertation has examined two key cytokines for osteoclastogenesis
regulation (RANKL and M-CSF) and their opposing effects on bone biomechanics. This
concluding chapter will highlight the novel findings from the three major animal studies
and their pilots studies detailed in the previous three chapters, and propose suggestions on
future direction based on these findings.
6.1 Conclusions
Studies in this project have characterized the in vivo catabolic effects of RANKL
as the late stage regulator and final effector for osteoclastogenesis on bone biomechanics;
examined and proposed RANKL-induced skeletal deterioration model as a novel animal
model for osteolytic skeletal diseases; and characterized the in vivo anabolic effects of MCSF as the early stage regulator for osteoclastogenesis and its potential of acting as an
innovative anabolic therapy for osteoporosis. During the above explorations, a series of
novel findings has been concluded in which the details are described as below.
1. Daily injections of soluble RANKL directly activated osteoclastogenesis and
stimulated general bone turnover rates, resulting in hypercalcemia.
2. Soluble recombinant RANKL caused severe catabolic effects on both cortical and
trabecular bone in a short period of time. These effects include: increases in bone
resorption, reduces in both cortical and trabecular bone volume, decreases in both
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cortical and trabecular bone mineralization, impairments in cortical bone
architecture and reduces in cortical bone strength.
3. Excessive RANKL levels led to a coupling-related increase in bone formation at
the periosteal surface of cortical bone. However, these increased bone formations
were insufficient to counteract deleterious effects on other areas.
4. Therapies targeting inhibition of RANKL might be a viable approach in treating
skeletal complications of high-turnover bone diseases like osteoporosis.
5. The RANKL injection study on mice has some limitations, including the lack of
an obvious dose-response for many of the endpoints. We believe that a lower dose
range would have provided a clearer dose response for the majority of parameters.
Dose-dependent weight loss and hypercalcemia indicated that RANKL
administration at 2 mg/kg was an excessive dose that resulted in toxicity.
6. In the RANKL infusion study, we have used soluble RANKL to develop a new
animal model for high-turnover bone diseases without obvious complications or
toxicities. This novel animal model recapitulates many of the deleterious skeletal
changes associated with postmenopausal osteoporosis in which details are
compared and listed below:
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Table 6.1 Comparisons of bone functional changes between postmenopausal women and
RANKL induced bone loss model

Postmenopausal women

RANKL induced bone loss model

•

Bone mineral density decreases

•
•

Cortical and trabecular bone volume lost
Trabecular bone mineralization reduced

•

Integrity of trabecular bone geometry
reduces

•
•

Trabecular bone volume decreased
Trabecular connectivity density reduced

•

Medullary cavity increases

•

Endocortical bone resorption rate
increased
Endocortical bone area increased

•
•

Periosteal diameter (bone size) increases •

•

Fracture risk increases

•

Periosteal bone formation rate increased
Bone strength at femur mid-diaphysis and
femoral neck reduced

7. Bone turnover rates responded to increased circulating RANKL levels with a
coupled increase in both bone formation and resorption. Due to the coupling
phenomena, bone formation markers increased accordingly with a delay relative
to the increase in resorption, and correlates with the activation sequence in normal
skeleton remodeling cycle.
8. The lower dosage of RANKL infusion induced trends of decrease in trabecular
bone parameters without corresponding changes in serum bone turnover markers
and circulating RANKL levels. These results suggested that RANKL may be
capable of causing deleterious effects in bone volume and structure in the absence
of changes in circulating levels of RANKL itself, or biochemical markers of bone
turnover.
9. RANKL administrations induced a homeostatic response that attempts to
minimize the severity of bone loss. The osteoporotic phenotype of OPG-deficient
mice shows that even a lifetime of unopposed RANKL activity does not lead to
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complete resorption of the skeleton (Bucay, Sarosi et al. 1998). It is therefore
likely that compensatory mechanisms eventually defend the skeleton against the
extremes of bone loss, perhaps via a feedback increase in bone formation.
10. Analysis of the calcium content from abdominal aortas indicated that continuous
RANKL administration did not cause vascular calcification. It is possible that
systemic exposure to RANKL does not induce or exacerbate vascular disease.
Alternatively, RANKL-related changes in the vasculature might require a longer
infusion period or the presence of additional vascular insults or challenges. This
study utilized healthy rats, and it remains possible that RANKL could have
deleterious effects on the vasculature in animals that are more susceptible to
vascular diseases.
11. High dose M-CSF administration resulted in marked increases in trabecular bone
formation and general bone turnover rates. These novel findings indicated that MCSF dissociated bone remodeling which favored bone resorption, and have
demonstrated the potential of M-CSF as a potent anabolic agent for bone strength.
12. Systemic anabolic effects of M-CSF were reflected by the increases in body mass.
Mice treated with M-CSF gained significantly higher body weight from Day 3
and remained throughout whole course of the study.
13. In this study, we observed increases in both osteoclastogenesis and bone
formation activities. M-CSF receptors exist on surfaces of osteoclasts and their
progenitors but not osteoblasts. These findings indicated that M-CSF indirectly
stimulated bone formation through coupling of osteoblasts and osteoclasts.
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14. M-CSF induced trends of decrease in cortical bone parameters without changes in
bone strength. These observations on cortical bone were contradictory to previous
findings of increased cortical thickness in transgenic models over expressing MCSF (Abboud, Ghosh-Choudhury et al. 2003).
15. The evident increases in trabecular bone parameters and trend of decrease in
cortical bone volume indicated that M-CSF exhibits both anabolic and catabolic
effects with site-specific differences. These region specific observations are
similar to those induce by PTH.
16. Pilot studies of the M-CSF study indicated a dose dependent effect of M-CSF on
bone biomechanics. Analysis of the data also indicated that there is a dose
threshold for M-CSF to induce bone functional changes.
17. In summary, activations of later and early stages of osteoclastogenesis, through in
vivo administration of RANKL and M-CSF, induced general opposing changes on
bone volume, structure, mineralization and strength. RANKL directly stimulated
bone resorption and degraded bone biomechanical properties. The bone loss
animal model induced by RANKL exhibited a series of skeletal complications
similar to those observed in high-turnover osteolytic skeletal diseases such as
osteoporosis. On the other hand, administrations of M-CSF markedly stimulated
trabecular bone formation and had less of an influence on cortical bone. These
changes demonstrated the potential of M-CSF as an anabolic agent for
osteoporosis.
18. Findings in this project, such as the creation of a RANKL induced bone loss
model and characterization of M-CSF as an innovative anabolic agent for bone
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biomechanics, could provide a useful tool and information for further explorations
on the battles with human skeletal diseases.
6.2 Recommendations
6.2.1 RANKL Induced Bone Loss Model
Studies in this project have created an animal bone loss model induced by
RANKL administrations. To make this novel model a practical tool for future studies on
the field of skeletal diseases, further studies on optimizing this model are recommended:
1. In our studies, we administrated RANKL at high dosages via daily injections on
mice and long-term continuous administrations with lower dosages on rats, to
ensure the fully catabolic consequences. The amount of RANKL administered to
animals appeared excessive. Future studies examining the minimal dosage and
administration periods of RANKL on mice or rats will be helpful to lower the
toxicity, expense, studies period and increase the practicality of the model. It is
recommended to further examine the duration of the bone destructive status in this
model which is the body’s natural recovery response after RANKL induced bone
loss.
2. It will be of further interest to examine the expression levels of up-stream
cytokines, such as PTHrP, IL-1, IL-6, M-CSF and TGF-β in this RANKL induced
bone loss model. These cytokine expression levels will provide valuable
information on the mechanisms of cytokine interaction, indications of skeletal
homeostasis from the protein level and predict the skeletal responses.
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3. Future studies are recommended to examine the therapeutic agents for skeletal
diseases, such as OPG, PTH, and bisphosphonates with this model. These studies
may provide further information on therapeutic efficacy and disease mechanisms
that were not captured by other models.
6.2.2 Development of M-CSF as a Novel Anabolic Agent for Osteoporosis
In this project, M-CSF showed good potential as an innovative anabolic agent for
bone biomechanics. However, due to the limited in vivo data available in the literature,
the detailed mechanism and functional effects of M-CSF on the skeletal system require
further examination. Future recommended studies are:
1. Lower efficacious doses and optimum administration periods and routes of MCSF, with the capability to induce anabolic response without causing toxicity or
immune responses, remain to be characterized.
2. Mechanisms of coupling, such as signal transductions through osteoclastsosteoblasts direction interaction, and changes in cytokine levels in bone
microenvironment after coupling is triggered by M-CSF, are also recommended
for further examination.
3. Examinations of M-CSF efficacy on disease models, such as OVX and RANKL
induced bone loss model as described in this study, will provide further
information on this anabolic agent in addition to those observed in healthy mice
of this project.
4. Soluble M-CSF exhibited a relatively short clearance time in the circulation
(Bauer, Gibbons et al. 1994). Modifications on molecular structures or drug
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delivery methods, aiming to improve the pharmacokinetic and pharmacodynamics
of this protein remain to be developed.
5. The antiresorptive potential of M-CSF indicated by in vitro studies was not
observed in current in vivo studies. These antiresorptive effects, if observed in
future studies in vivo, will greatly enhance the potential of M-CSF being a
therapeutic agent for osteolytic skeletal diseases with both anabolic and
antiresorptive effects.

166

6.3 References

Abboud, S. L., N. Ghosh-Choudhury, et al. (2003). "Osteoblast-specific targeting of
soluble colony-stimulating factor-1 increases cortical bone thickness in mice." J
Bone Miner Res 18(8): 1386-94.
Bauer, R. J., J. A. Gibbons, et al. (1994). "Nonlinear pharmacokinetics of recombinant
human macrophage colony-stimulating factor (M-CSF) in rats." J Pharmacol Exp
Ther 268(1): 152-8.
Bucay, N., I. Sarosi, et al. (1998). "osteoprotegerin-deficient mice develop early onset
osteoporosis and arterial calcification." Genes Dev 12(9): 1260-8.

APPENDICES

168

Appendix A: Examination of M-CSF Protein Degradation

The M-CSF protein used in this project was donated by Chiron, manufactured 15
years ago. To examine potential protein degradation, SDS-PAGE and Western Blot
analyses were performed.
Materials and Methods
The protein sample (3.9 mg/ml) was serial diluted (10%, 1%, and 0.2%) then
mixed with an equal volume of loading buffer. For the SDS-PAGE gels (Piece), 10µl of
each concentration was loaded. Thus, 19500ng, 1950ng, 195ng and 39ng of M-CSF were
loaded per lane. The molecular weight marker, Kaleidascope (Biomad) was loaded (5 µl).
A voltage of 120V for 60 minutes was used. The SDS-PAGE gel was then stained with
Coomassie Blue to visualize the protein. Western blot were used to confirm that the
protein bands observed on the SDS-PAGE gels were M-CSF and its degraded isoforms.
The primary antibody to M-CSF was a rabbit monoclonal from Genetex. A goat antirabbit IgG antibody was used as the secondary antibody. All procedures for Western Blot
followed the instructions from Bio-Rad.
Results
The serially diluted samples of M-CSF resulted in multiple bands on the gels.
Based on comparison of the loaded samples, approximately 2-8% of the protein was
degraded. The antibodies detected the lower molecular weight bands on the western blots,
indicating that both the primary band and the degraded bands were M-CSF (Figure A.1).
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Figure A.1 SDS-PAGE gel and Western blot membrane analysis of the recombinant M-CSF used
in these studies confirmed the degradation. The lanes labeled 100%, 10%, 1% and 0.2%
contained 19500ng, 1950ng, 195ng and 39ng of M-CSF, respectively. The observed degradation
is between 2 to 8% of the total protein in the sample. MW: Molecular weight.

Appendix B: Low Dose Administration of Macrophage-Colony Stimulating Factor
in Mice

Part of the M-CSF pilot study I data submitted to Rocky Mountain Bioengineering
Symposium as a conference article in 2004: “Low dose administration of macrophage
colony-stimulating factor in mice.” Biomed Sci Instrum. 2004;40:93-8.
Yuyu Yuan, Virginia L. Ferguson*, Steven J. Simske*, Ted A. Bateman
Department of Bioengineering, Clemson University, Clemson, SC 29634
*BioServe Space Technologies, University of Colorado, Boulder 80309

ABSTRACT
Keywords: M-CSF, CSF-1, bone, mice, anabolic, osteoblast, osteoclast
Macrophage-Colony Stimulating Factor (M-CSF) is critical for osteoclast differentiation
and development. It has been previously observed that M-CSF administration and overexpression in mice causes an increase in cortical bone formation. We hypothesize that
M-CSF increases osteoblast activity indirectly via coupling of these two bone cells. In
this study, we examined the impact on bone properties of relatively low doses of M-CSF
in mice. Four groups of seven-week old C57BL/6J mice were used: (1) baseline (age)
controls, (2) placebo controls, (3) 10µg/kg/day M-CSF, (4) 100µg/kg/day M-CSF.
Injections were administered daily for the 21-day study. Three bone labels of calcein and
tetracycline were alternately administrated (days 0, 9 and 18) to allow quantification of
new bone formation. MicroCT scans (15 micron resolution) were performed on the
proximal end of the right tibiae (1.0 mm section of trabecular bone) and left femur middiaphysis (0.25 mm cortical section). Dry mass, mineral content and percent mineral
composition were obtained from the left tibiae. Functional changes were not detected in
the bone of these mice receiving low doses of M-CSF. In particular, as previous studies
have reported in mice receiving high doses of M-CSF or transgenic mice overexpressing
bone specific M-CSF, changes to cortical bone did not occur with the lower doses. This
may indicate that high doses of M-CSF and/or longer periods of administration may be
required to observe the anabolic effect of M-CSF on mouse cortical bone.

INTRODUCTION
Macrophage-Colony Stimulating Factor (M-CSF or CSF-1) is a haematopoietic growth
factor that is produced mainly by connective tissue cells, including osteoblasts (Felix,
Halasy-Nagy et al. 1996). M-CSF is essential for the cells from the mononuclear
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phagocytes lineage, from which osteoclasts are derived (Kodama, Nose et al. 1991). It is
known that M-CSF facilitates monocyte survival, monocyte-to-macrophage conversion,
and macrophage proliferation (Corboz, Cecchini et al. 1992; Fixe and Praloran 1997). In
vitro, it has been shown to promote osteoclastogenesis in bone (Corboz, Cecchini et al.
1992; Sundquist, Jackson et al. 1995; Sarma and Flanagan 1996). The ability of M-CSF
to stimulate osteoclast in vivo has been confirmed by using the M-CSF-deficient
osteopetrotic (op/op) mouse model (Kodama, Yamasaki et al. 1991; Sundquist, Jackson
et al. 1995; Abboud, Woodruff et al. 2002). Repeated injections of M-CSF increased the
number of osteoclast, which lead to partial or complete correction of the osteopetrotic
defect. A dose-dependent relationship was observed during these treatments. These
studies demonstrate the ability of M-CSF to increase bone resorption in mice deficient in
osteoclasts.
However, recent studies on transgenic mice targeted expression of M-CSF showed
increased cortical thickness and bone mineral density (Abboud, Ghosh-Choudhury et al.
2003). This osteoblast specific expression of soluble M-CSF greatly increased levels of
M-CSF in the bone, resulting in increased bone formation rates at the endocortical
surface. Our group has observed similar results with the administration of M-CSF
improving material and mechanical properties of cortical bone (Hermann 2000). The
increase in strength was mediated by a greater percent mineral composition, rather than
an accelerated bone formation. An increase in percent mineral composition is observed
with the administration of anti-resorptive therapies (Bateman, Lacey et al. 1999;
Bateman, Dunstan et al. 2000).
These findings highlight the complex and important role of M-CSF in bone physiology,
and demonstrated its potential as an unconventional therapy for osteoporosis. Less clear
evidence suggests that M-CSF actually inhibits mature osteoclast activity, potentially
acting as an agent that promotes bone formation via coupling by promoting immature
osteoclasts, but limiting the amount of bone resorption by mature osteoclasts. This
unique role in osteoclast development and survival may have a positive effect on both
osteoblast’s and osteoclast’s increasing bone mass rather than inhibiting bone formation
as current anti-resorptive therapies do. To explore this hypothesis and to determine the
optimum M-CSF dose for increasing cortical strength, we are examining two different
doses of M-CSF (100 µg/kg/day and 100µg/kg/day). These doses are 10% and 1% of the
high dose previously examined by our group (Hermann 2000), and more similar to the
dose of teriparatide (parathyroid hormone amino acids 1-34) that produces an anabolic
effect (Andreassen, Ejersted et al. 1999).

METHODS
In this study, 75 C57BL/6J (Jackson Labs, Bar Harbor, Maine, USA) mice seven-weeks
in age were randomly assigned to four groups: (1) baseline (age) controls, (2) placebo
controls, (3) 10µg/kg/day M-CSF, and (4) 100µg/kg/day M-CSF. The baseline control
group was sacrificed at the beginning of the study, the placebo, M-CSF (10µg/kg) and MCSF (100µg/kg) groups were administered saline, 10µg/kg M-CSF and 100µg/kg M-CSF
through this 21-day study (i.p.). The initial weights of all mice ranged from 18-22 gram,
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the weights were monitored daily. During this experiment, Calcein (s.c., 20 mg/kg, at
days 0 and 18) and Tetracycline (s.c., 20 mg/kg, at day 9) were administered to all mice
to allow the quantification of bone formation rates. Clemson University animal care and
use committee approved the animal protocol for this study.
At the end of the study, all the mice were sacrificed via exsanguinations and followed by
cervical dislocation. Afterwards, the femora and tibiae were removed and cleaned off all
non-osseous tissue. The right femora and tibiae were fixed with 10% neutral buffered
formalin for 48 hours and then stored in 70% ethanol. The right femora was air dried and
embedded in Epo-Quick epoxy (Buehler, Lake Bluff, IL), then sectioned at mid-diaphysis
using a low speed saw (Buehler, 300µm diamond blade). Photographs of the bone were
taken at 50X under three different filters (FITC, Fs05, DAPI) to view the bone labels.
Quantitative histomorphometric analysis will be performed on these cross-sections.
The proximal end of the right tibiae was scanned with MicroCT (SCANCO Medical,
µCT20, Zurich, Switzerland); trabecular bone approximately 1.0 mm beneath the growth
plate was analysis. The left femora were dried for 48 hours and a MicroCT scan was
performed on the mid-diaphysis. A 0.25 mm thick section of cortical bone was analyzed
(15 micron resolution, 9 microns per slice, 28 slices); total volume and bone volume were
obtained for all groups (Figure 1). Mineral content of the left tibiae was analyzed, dry
mass (Dry-M, 105C for 24 hours) and mineral content (Ash-M, 800C for 24 hours) were
obtained on the proximal end and the diaphysis. A one-way-ANOVA statistical
comparison was used on all these tests, with a Tukey follow-up. Data are reported as
mean +/- standard deviation with 95% statistical significance (type I error).

RESULTS
The mice weights increased normally during this 3-week study, the difference between
placebo and M-CSF treated groups was not significant. After examining the trabecular
volume, trabecular number, trabecular thickness, trabecular spacing and the ratio of bone
volume by total volume of the tibiae proximal end, changes between placebo, 10µg/kg
M-CSF and 100µg/kg M-CSF groups were not significant, the bone volume/total volume
increased with age compared to baseline group. No significant changes were observed of
the dry mass and ash mass of the tibiae proximal end and diaphysis. MicroCT scan of the
femora mid-diaphyseal cortical bone showed a normal increase of total volume and bone
volume with age, but significant changes between placebo and M-CSF treated groups
were not observed.
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Figure 1. MicroCT scan of cortical bone from the femur mid-diaphysis, 0.25 mm thick.
ScanCo Medical, MicroCT 20 Scanner (15 micron resolution, 9 microns per slice, 28
slices).
Femora Diaphysis, 0.25 mm Thick
Cortical Volume

0.22
0.21
0.2
0.19
0.18
0.17
0.16
0.15
0.14
0.13
0.12
Baseline

Placebo

10ug/kg M-CSF

100ug/kg M-CSF

Figure 2. MicroCT scan of Total/Bone Volume (mm2) of cortical bone in the femur,
0.252mm thick. No significant differences were observed between groups.
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DISCUSSION
Previous studies with op/op mice showed increased osteoclasts and macrophages, thus
proving that M-CSF is a potent growth and differentiation factor for cells of the
mononuclear phagocyte lineage. Discrepancies between the recoveries of osteoclasts and
macrophages with respect to locations and dose responsiveness on the op/op mice was
reported (Sundquist, Jackson et al. 1995), these suggest different regional sensitivities of
these cells and their precursors to M-CSF for survival and differentiation. For this study,
low-dose M-CSF administration had no significant on cortical bone, as observed in other
studies (Hermann 2000; Abboud, Ghosh-Choudhury et al. 2003). It is important to note
that M-CSF administration may have an anabolic effect on cortical bone, but not
trabecular. This difference was observed for mice over-expressing M-CSF (but not
examined for our previous study administering M-CSF daily) (Hermann 2000; Abboud,
Ghosh-Choudhury et al. 2003). But it has been reported in previous study that increased
cortical thickness and bone mineral density were showed with high level of M-CSF
expression and long period of time [7], this may indicate that higher doses and longer
period of administration time may be necessary to induce noticeable effects in cortical
bone.

CONCLUSIONS
Daily administration of 10µg/kg and 100µg/kg M-CSF in mice produces no functional
changes in cortical bone properties. It is hypothesized that high doses (effectively
flooding M-CSF receptors), and potentially longer period of administration, is needed to
demonstrate the anabolic effect of M-CSF.
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